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Abstract 
 
Magnetic Resonance Spectroscopic Imaging (MRSI), a functional MR imaging 
technique, has proven via the identification of metabolite biomarkers to be useful in the 
diagnosis and prognosis of numerous diseases, for example brain tumours. However, 
a number of factors impede its routine clinical use: i) long acquisition times mean its 
use is limited to low resolution 2-dimensional slabs, ii) large quantity of data produced 
means its interpretation can be time consuming and iii) data quality can be variable 
and therefore interpretation can be difficult for a non-expert. Further developments in 
MRSI are designed to reduce the impact of these issues. The focus of this work is to 
address some of the above issues; developing acquisition protocols and optimising 
analysis methods in order to increase the clinical feasibility of MRSI. Within this study 
a fast-MRSI protocol has been developed for absolute metabolite quantitation and has 
demonstrated its feasibility for clinical use, accurately reproducing data in a shorter 
clinically feasible acquisition time. An experimentally derived fitting model has been 
developed which increases metabolite measurement accuracy. Finally, a 3D MRSI 
protocol has been successfully optimized allowing robust metabolite information to be 
mapped throughout the brain.  
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1. Introduction 
1.1 Developments in Magnetic Resonance Spectroscopic Imaging (MRSI. 
1H Magnetic Resonance Spectroscopic Imaging (MRSI) allows metabolite quantities to 
be mapped over a volume of interest (VOI). Spectra are acquired over multiple voxels 
and spectral features can be identified to map metabolism within the body for example 
the brain. Metabolism can be altered within the body, if there is a change in tissue 
composition for example the presence of a brain tumour. MRSI can be used to monitor 
this and therefore discern between healthy and diseased tissue. This thesis will focus on 
developments in acquisition and analysis of MRSI in the brain. 
1.2 MRSI in Clinic: It’s Advantages and Limitations. 
MRSI is a non-invasive functional MR imaging technique. It has proven, via the 
identification of metabolite biomarkers, to be useful in the diagnosis and prognosis of 
numerous diseases such as; brain tumours (1–3), neurodegenerative diseases (4) and 
neuro-metabolic disorders (5,6).  Although widely used in research its routine clinical 
adoption has been slow due to a number of limiting factors: i) long acquisition times mean 
its use is largely limited to low resolution 2-dimensional slabs, ii) the large quantity of data 
produced means its interpretation can be time consuming and iii) data quality can be 
variable and therefore interpretation can be difficult for a non-expert.  
1.3 Research Motivation 
Developments in MRSI are needed in order to make its use in the clinic more feasible. 
Improvements in acquisition time, analysis and protocol optimisation would aid in its 
routine clinical implementation. 
 2 | P a g e  
 
1.4 Aims and Objectives 
1. Investigate the effect of both acquisition parameters and fitting methods on 1H 
MRSI reproducibility. 
2. Investigate the effect of fast-MRSI techniques on accuracy for absolute metabolite 
quantitation. 
3. Evaluate the use of fast-MRSI techniques in clinical practice. 
4. Develop and optimise a 3D-MRSI protocol and evaluate its effectiveness with 
respect to data quality and clinical feasibility. 
1.5 Thesis Organisation 
The principles and applications of magnetic resonance imaging and spectroscopy, along 
with a literature review of fast MRSI in the brain has been summarised in Chapter 2. 
Chapter 3 investigates the influence of the macromolecule baseline on 1H MRSI 
Reproducibility. As previously stated in Section 1.2 one of the issues with MRSI is that 
data quality can be variable. Robust protocol designs are important in order to minimise 
error within spectral data. Due to the strong overlap of Macromolecular signals (MM) with 
metabolites of interest found within the brain; error can be introduced to the spectral fitting 
if the MM content is not fully characterised. A number of methods have been proposed, 
which either act to reduce the MM contribution with acquisition methodology or by 
accounting for it within the analysis using a specialised fitting model. This chapter 
addressed this issue by comparing the use of a simulated and experimental MM analysis 
schemes and different acquisition methods. Their effect on the reproducibility of 1H MRSI 
spectra were evaluated using coefficients of variance (COV’s %) and the mean metabolite 
concentrations were also determined for each method. This work has been presented as 
a poster presentation at the ISMRM 23rd Annual Meeting & Exhibition 2015 and has also 
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been peer reviewed and published within the Magnetic Resonance in Medicine Journal 
(7). Although reproducibility studies exist within the literature and previous comparisons 
have been made between simulated and experimental baseline models; this was the first 
study to investigate the effect of both echo time and macromolecular analysis schemes 
on the reproducibility of 2D 1H MRSI data at 3Tesla. This study was designed to help aid 
in the protocol design for clinical studies.  
As stated previously in section 1.2, long acquisition times have often precluded the routine 
clinical use of MRSI. Chapter 4 addresses this issue by testing the fast-MRSI technique 
sensitivity encoding (SENSE) and the “gold standard” reduced resolution technique in 
their ability to reconstruct the fully sampled water reference data. Their ability to do so 
was established through the construction of Bland Altman plots, the calculation of mean 
differences and metabolite concentration comparisons. The work detailed in chapter 4 
has been presented as a poster presentation at the Joint Annual Meeting ISMRM-
ESMRMB 2014 and has also been peer reviewed and published in Magnetic Resonance 
in Medicine Journal Volume 73, Issue 6 June 2015. To our knowledge this was the first 
study to use SENSE for the purpose of water reference data collection. 
The clinical implementation of the protocol developed in chapter 4 is investigated in 
Chapter 5. Spectroscopy data was acquired for 15 patients to test and validate the 
protocols use in the clinic and establish its clinical value for the determination of 
neurocognitive deficit. Quality control parameters such as signal-to-noise ratio (SNR) and 
water line width (FWHM) were calculated for each dataset in order to establish the 
protocols accuracy. Individual patient metabolite concentrations were also determined 
and structural images used to assess any post tumour/treatment effects in the parietal 
white matter region of the brain. The translations of protocols to the clinic are not always 
successful, therefore studies of this kind are needed to assess their efficacy. 
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Long acquisition times have largely limited the use of MRS to low resolution 2D slabs. 
Chapter 6 shows the development of a 3D MRSI protocol on volunteers for use clinically 
and in research. The extension to 3D would prove useful for clinical studies to allow more 
information on metabolism to be provided throughout the brain. It would be particularly 
useful for studies of brain tumours where heterogeneity may not necessarily lie within the 
axial plane. The move towards more whole brain spectroscopic imaging (via Spin-Echo 
sequencing) would be particularly desired to provide better sampling (increased number 
of voxels) across the brain. Accuracy of this method was assessed using QC thresholds, 
highlighted previously, in order to establish any data loss (via number of voxels) due to 
poor quality data. Outer volume lipid levels were also used to test the efficacy of outer 
volume lipid removal using lipid suppression techniques. The reproducibility of the Spin-
Echo protocol was also calculated in order to establish its robustness. To the best of our 
knowledge this is the first study to look at the combination of a spin echo with SENSE and 
lipid nulling to establish its reproducibility and the clinical feasibility of this methodology. 
The final chapter 7 includes the conclusions and discusses potential future work in the 
developments of MRSI acquisition and analysis methods.  
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2 MRSI Principles and Applications 
2.1 How the MR signal is acquired 
2.1.1 Basic Principles 
Nuclear spin is a fundamental quantum mechanical property of matter. An odd number of 
protons and/or neutrons within the nuclei will produce a net spin and magnetic moment. 
The human body is made up of ~75% water; the proton nuclei 1H within the water have a 
net spin and magnetic moment. Therefore, due to the proton nuclei’s high abundance in 
tissue and Nuclear Magnetic Resonance (NMR) sensitivity (high gyromagnetic ratio) the 
hydrogen nucleus is most commonly used for both magnetic resonance imaging and 
spectroscopy. The hydrogen nuclei interact with the main field of the MR Scanner and the 
protons experience a torque due to this external field. The proton in turn tries to align itself 
to the field causing it to precess around the direction of the field. The frequency ω0 of this 
precession is proportional to the external magnetic field B0 as defined by the Larmor 
Equation: 
Equation 2-1 Larmor Equation 
!" = $%" 
Where: 
 γ is the proton gyromagnetic ratio=2.7 x 108 rad s-1 T-1 
The proton can precess in two possible stable states (Figure 2-1): parallel (almost aligned 
with B0) and anti-parallel (aligned almost opposite to B0). The magnetic moment is at an 
angle to the external field B0 and therefore independent of orientation will trace a circle 
around the direction of the field (represented by the dashed line). The ratio of protons 
spinning in these two states is dependent on its energy, the strength of B0 and inversely 
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on temperature. Both states are stable but statistically the distribution of protons favours 
the lower energy parallel state. The protons can change state by either gaining or losing 
energy in the form of a photon i.e. electromagnetic radiation. 
 
Figure 2-1 Parallel and Anti-parallel proton states in an external magnetic field B0 
highlighting the magnetic moment precession 
 
 
The energy difference between the parallel and anti-parallel state is directly proportional 
to B0 and the frequency of the electromagnetic radiation is equal to the Larmor frequency 
ω0 therefore also equates to equation 2-1. Therefore, it can be shown that the 
precessional frequency is equal to the frequency of radiation required to cause a transition 
between the two states.  
At equilibrium, a collection of proton nuclei are out of phase with each other, and the 
direction of magnetic moment vectors will be spread out evenly in the plane perpendicular 
to B0. Due to the high number of protons groups of vectors can be simplified to an average 
magnetic moment or “Spin” which precesses at the same frequency ω0. The net 
 7 | P a g e  
 
magnetization M0 can therefore be defined as the vector sum of the spins. M0 is aligned 
exactly with B0 and is defined as the z direction. 
2.1.2 How the MR signal is measured 
The magnetization within the body M0 is of a much smaller order (microtesla) compared 
to the external field B0, most common clinical scanners being an order of 1.5 or 3 Tesla. 
Thus, it cannot be measured reliably at equilibrium. However, if the magnetization is 
tipped 90 degrees from the z axis, using a resonant radiofrequency (RF) pulse, into the 
transverse x-y plane the magnetization can be detected and measured easier as the 
measurement can be made in a separate axis to the external field B0. The RF pulse 
defines the flip angle (a) applied to the magnetization and will cause the spins to align. 
For a simple RF pulse which is turned on and then off the flip angle is defined as: 
Equation 2-2 Flip Angle 
a = g%&'( 
Where: 
B1 is the strength of the RF magnetic field 
g is the gyromagnetic ratio 
tp is the duration of the pulse 
A 90-degree RF pulse will cause the magnetization to tip fully into the transverse plane. 
A 180-degree pulse is applied by doubling the length/amplitude of a RF pulse. The 
strength of the pulse can also be altered to produce different flip angles. M0 precesses 
clockwise into the transverse x-y plane inducing a voltage into the receiver coil. 
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Once the RF pulse has flipped the protons into the transverse plane, they will relax back 
to the equilibrium i.e. longitudinal position M0 once the pulse is removed. At this point M0 
is comprised of two magnetization components transverse magnetization Mxy and 
longitudinal magnetization Mz. The first decays along the transverse axis due to spin-spin 
relaxation with a characteristic time T2. This parameter also contains a T2* component 
which takes into account the dephasing of spins due to susceptibility field inhomogeneity 
effects. Mz is the restoration of the longitudinal magnetization at a tissue dependent time 
T1 (spin-lattice relaxation).   
T2 relaxation is modelled as an exponential decay where the transverse components of 
Mxy decay or dephase with respect to time constant T2. As defined below: 
Equation 2-3 T2 Relaxation )*+ = )",- ./0 
T2 is defined as the time it takes for the transverse magnetization to fall to approximately 
37% of the original value of Mxy.  
T1 relaxation is modelled as an exponential growth process defined by the following 
equation: 
Equation 2-4 T1 Relaxation )1 = M" 31 − e-78&9 
Where Mz is the longitudinal magnetization 
           M0 is the maximum magnetization 
           t is time 
           T1 is relaxation time 
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T1 is modelled as a first order time constant and therefore is defined as the value at which 
Mz recovers up to 63% of its maximum value M0 for a particular tissue signal. Different 
tissue types have different T1 relaxation times. If a 180-degree inversion pulse is applied, 
reversing the longitudinal magnetization Mz, the Mz will then begin to recover via T1 
relaxation going from negative to positive. A signal can be generated at time TI which is 
based on the individual T1 of each tissue type. Because of this a null point can be found 
for different tissue signals. The null point TInull for a particular tissue type is defined as: 
Equation 2-5 Tissue null point equation :;<=>> = :1 ?ln(2) − EFG1 + ,-/I//&KL 
If TR>>1 then the equation simplifies to: 
Equation 2-6 Simplified tissue null point equation :;<=>> = ln(2) × :1 
See figure 2-9 for a demonstration of this process in the nulling of lipid signals. 
The receiver coil is designed to only be sensitive to magnetization in the transverse plane 
Mxy. The coil sees an oscillating field inducing a voltage which varies at the Larmor 
frequency creating the readout signal. The signals amplitude decays exponentially to zero 
as the protons dephase rapidly from each other. This can typically take up to a few 
seconds. For example, water T2 relaxation times for white matter and gray matter within 
the brain at 3T of 110ms and 80ms have been found (8). This is signal is known as a Free 
Induction Decay (FID) (Figure 2-2). 
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Figure 2-2 Free Induction Decay (FID) 
For slice selection and spatial localization of MR signals echoes are created using 
different pulse sequences. 
2.1.3 MR Image Formation, Localisation and Pulse Sequences 
Magnetic field gradients are applied to form the pulse sequence required to localize the 
signal. Pulse sequence diagrams are used to illustrate the steps required to acquire the 
MR signal. As a simple example to demonstrate the steps required: Figure 2-3 illustrates 
this for a gradient echo sequence. For example, in the gradient echo sequence a slice 
selective gradient Gss is applied simultaneously to the RF pulse. This restricts the 
excitation to the desired slice within the body.  
A phase encoding gradient GPE is applied for spatial localisation. Phase encoding works 
by applying a magnetic field gradient which in turn dephases spins along the direction of 
 11 | P a g e  
 
the applied gradient. Once the gradient is turned off, the signal from each pixel will have 
a different phase shift dependent on its position along the gradient. The individual signal 
amplitudes can be extracted out because of this difference using a Fourier transform.  
In MRI, a frequency encoding gradient GFE is also applied, as the data is acquired to 
encode the data as spatial frequencies. This sequence gets repeated for every line of 
data/each phase-encode gradient value until the k-space matrix is filled. K- space is a 
spatial frequency domain which maps the spatial frequencies contained within an image. 
Each point in k-space corresponds to a spatial frequency component with an associated 
amplitude. A Fourier transform can be applied to the k-space map to produce the MRI 
image using these components.  
Two pulse sequence parameters are echo time TE and Repetition Time TR. TE is the 
time between the RF pulse to the center of the gradient echo where the signal is 
refocused. Signal-to-noise decreases with increasing TE. This is due to the dephasing of 
the MR signal and therefore lower signal measured during the readout. The parameter 
TR is defined as the time period between each repeated excitation RF pulse. The total 
scan time can be defined as: 
Equation 2-7 Scan Time Calculation NOPF	'RS, = TNU	 × 	TVW 	× :X 
Where: 
NSA is the number of signal averages 
NPE is the phase encoding matrix size 
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Figure 2-3 Gradient Echo Sequence 
2.2 Magnetic Resonance Spectroscopy (MRS) Acquisition 
2.2.1 MRS Basics 
The protons imaged in 1H MRS are subject to slightly different magnetic environments. 
The local magnetic fields of different chemical compounds will vary, resulting in a 
chemical shift in the local Larmor frequency. The compounds are shifted to a different 
frequency ω0 (j) according to their molecular environment type j, pH is also known to 
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have an impact on w0(j). This frequency measurement is in rads-1 but is often presented 
as parts per million (ppm) as defined below: 
Equation 2-8 Larmor Frequency Y = 	!"(Z) − !"([,\)2]%" × 10_ 
Where: 
ω0(j) is the frequency of the metabolite in rads-1 
 ω0(ref) is the frequency of the reference metabolite in rads-1 
B0 is the strength of the external magnetic field in Tesla 
The chemical shift of a nuclei is dependent on the effect of the surrounding electrons 
within the molecules. These electrons partially shield the nucleus from the external 
magnetic field B0. Therefore, differences in chemical composition will cause the molecule 
to resonate at a unique frequency. As shown in Equation 2-4 this will result in frequency 
shifts between different molecules allowing the separation and identification of different 
metabolites as they will appear at different positions within the spectrum. J coupling is the 
process where metabolite peaks can split due to the effect of nuclear spins from 
neighboring nuclei within the same molecule. In 1H MRS this can result due to a single 
neighboring proton, resulting in a doublet peak, or more than one, resulting in a multiplet 
pattern. 
In MRS these different compounds can be measured spectrally providing information on 
the chemical/metabolic processes that are occurring within that volume. A typical brain 
spectrum is comprised of a number of metabolite, lipid and macromolecular signals (see 
section 2.4). The spatial localisation of these signals can be split into two categories 
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Single Voxel Spectroscopy (SVS) and multi voxel techniques known as MR Spectroscopic 
Imaging (MRSI).  
2.2.2 Single Voxel Spectroscopy (SVS) 
Single voxel spectroscopy (SVS) acquires a single spectrum from a voxel placed within a 
specific location (e.g. the brain).  Three slice selective mutually orthogonal pulses are 
applied in order to collect the echo signal from that single intersecting volume in space 
i.e. the voxel (Figure 2-4). SVS is most commonly acquired using a Point RESolved 
Spectroscopy (PRESS) sequence which uses a single slice selective 90-degree pulse 
and two 180-degree slice selective refocusing pulses in order to acquire spectra from a 
single volume. 
 
Figure 2-4 Voxel selection using three mutually orthogonal pulses 
Any outer volume signals are either crushed using dephasing gradients and/or through 
phase cycling of the RF pulses (9).  
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SVS has been widely adopted clinically due its robustness, short scan times, good field 
homogeneity, and ease of implementation, processing and interpretation. However, 
because of its restriction to data collection from one single location, the number of 
appropriate clinical applications are restricted. For example, it provides limited information 
in disease cases where heterogeneity may exist e.g. in tumours or in cases where the 
area of interest is not known. 
2.2.3 Multi-voxel: Magnetic Resonance Spectroscopic Imaging (MRSI) 
Two-dimensional MRSI acquisitions are acquired by applying phase encoding in two 
directions for spatial localisation. Unlike MRI it does not have a frequency encoded 
gradient as we are interested in the individual chemically shifted frequencies. The 
acquisition is stepped through the voxels after every complete sequence defined by 
repetition time TR.  MRSI is a multi-voxel technique which allows you to map metabolites 
across a predefined VOI (2D PRESS MRSI shown in Figure 2-5) (8). MRSI is a promising 
technique for the study of diseases such as brain tumours since heterogeneity (9) and 
diffuse margins (10) are common features and can be observed more easily with MRSI. 
It can also be used to monitor neurodegenerative diseases such as Alzheimer’s (11) and 
neuro-metabolic disorders (12,13). MRSI is particularly useful in cases where the clinically 
relevant area may not be known in advance. Both SVS and MRSI are widely available 
clinically and can be used in conjunction easily with standard MRI examinations. 
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Figure 2-5 2D MRSI Plan 
2.2.4 3D MRSI 
Two-dimensional MRSI can be extended into 3 dimensions through the addition of an 
extra phase encoding direction, so the frequencies are spatially encoded in three 
directions. Metabolism can be mapped through multiple slices, useful in cases where 
heterogeneity may not necessarily lie in the axial plane and once again for diseases 
where the area of interest may not be known. 3D acquisitions can be categorized into 
two sections: Multi-slice 2D (Figure 2-6) and 3D MRSI. For 3D MRSI signal collection 
and SNR is considered to be more efficient as signal from the whole region is collected 
at all times (10). However, maintaining a homogenous field across a large VOI can 
prove difficult. Long acquisition times due to phase encoding in three directions may 
also hinder its use. Multi-slice 2D provides sharper slice profiles as it is not defined by 
the excitation pulse point spread function (10). Both techniques have long acquisition 
times and therefore require fast-MRSI techniques (section 2.2.7) in order to be deemed 
clinically feasible.  
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Figure 2-6 Example 3D-MRSI Plan 
2.2.5 MRS Pulse Sequences 
The Spin Echo sequence (Figure 2-7) allows the spins to dephase after the initial 90-
degree pulse after some time a 180-degree pulse is applied on the +y’ axis which flips the 
spins through 180 degrees about this axis. This reverses the spin phase angles, if the 
spin was located within lower magnetic field strength it will have been dephasing anti-
clockwise. The 180-degree pulse flips these spins so they appear to have been in a high 
field thus dephasing clockwise and vice versa for the initial high field spins. After the 90-
180 degree delay the spins will now continue to dephase and a spin echo will be formed 
as the spins come back into phase along the +y’ axis. Spin-echo relies on phase-reversal 
the signal decay will only depend on T2 (see section 2.1.5) and diffusion and not on the 
field inhomogeneity or tissue susceptibility. 
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Figure 2-7 Spin Echo Sequence 
Point RESolved Spectroscopy (PRESS) is based on the Spin Echo sequence and 
comprises of a single slice selective 90-degree pulse and two 180-degree slice selective 
refocusing pulses (Figure 2-8). Each pulse has a slice selective gradient on each of the 
principle axes in order to ensure only protons within the voxel/volume are excited.  
 
Figure 2-8 PRESS Sequence 
2.2.5 Water Suppression 
Due to the high abundance of water within the body, there is a large signal contribution 
from these protons within the acquired spectra. The brain water signal has a much higher 
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magnitude compared to the metabolites of interest. Therefore, as metabolite contributions 
are so much smaller, it is necessary to suppress the water signal to allow reliable and 
accurate measurement of the smaller metabolite signals. Water resonances have shorter 
T2 relaxation times compared to the metabolites and therefore suppression can be more 
effective at longer echo time TE. However, this method is insufficient and pre-saturation 
of the water signal prior to the localization pulse sequence is preferred. Water suppression 
techniques e.g. CHEmical Shift Selective pulses (CHESS) (11) uses frequency selective 
pulses in combination with well-defined flip angles in order to effectively suppress the 
water signal.  
2.2.6 Lipid Suppression 
Large signal contributions originating from peri-cranial fat can be observed at high levels 
within the brain. These signals can contaminate the spectra once again reducing the 
reliability and accuracy of the metabolite measurement. A number of methods have been 
proposed to either suppress (using outer volume suppression pulses i.e. Saturation 
Bands) or avoid exciting the outer volume lipid signals (pulse sequences such as STEAM 
and PRESS). Saturation bands can also be applied over the peri-cranial region which 
crush the lipid signal so it does not appear within the in-volume spectra. Inversion pulses 
can also be used to suppress the lipid signal. Lipids have a shorter T1 time comparison 
to metabolites and therefore can be nulled at an inversion time TI where the metabolite 
signal is non-zero and can be measured. Figure 2-9 illustrates how a SPectral Attenuated 
Inversion Recovery (SPAIR) sequence nulls the lipid signal so only metabolite signal is 
acquired.   
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Figure 2-9 SPectral Attenuated Inversion Recovery (SPAIR) Sequence to null lipid 
signals 
 
A 180-degree inversion pulse is applied. The lipid signals are nulled after an inversion 
delay with inversion time TI. At this point the metabolite peaks are inverted but non-zero. 
Therefore, the metabolite signals alone can be detected if an excitation pulse is applied 
at inversion time TI. 
2.2.7 Fast-MRSI Techniques 
2.2.7.1 Reduced Resolution 
Reduced k-space acquisition (reduced resolution) is a simpler MRSI technique, currently 
used as the “gold standard” technique at Birmingham Children’s Hospital.  This technique 
reduces scan time by sampling fewer points in k-space, resulting in a lower resolution 
scan. In order to obtain absolute concentrations, the outer rim of k- space is zero filled in 
order to increase the matrix to the correct fully sampled size. It can then be used as a 
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quantitation reference for higher resolution water suppressed scans. This effectively 
performs an interpolation of the missing data in spatial domain (12). 
2.2.7.2 Compressed Sensing 
Compressed sensing, first derived from mathematics in the literature of information and 
approximation theories, is a method which reconstructs signals from sparse data 
comprised of “random” linear combinations of signal values, much smaller than the 
original full data set (13). In MR, a small subset of k-space is acquired instead of full k-
space. MRI data is well suited to compressed sensing as it fulfills the following criteria: 
the resultant image is compressible and therefore is a sparse representation in a known 
transform domain. Any aliasing artefacts due to k-space under sampling are 
incoherent/noise like and non-linear reconstruction can be applied. Thus, compressed 
sensing can accurately reconstruct the fully sampled k-space data. By under sampling k-
space the acquisition time can be reduced. Compressed sensing can also be used in 
conjunction with sensitivity encoding (see section 2.2.7.3) allowing an even greater speed 
up of scan time. 
2.2.7.3 Sensitivity Encoding (SENSE) 
Fast-MRSI methods have been developed which act to reduce the number of phase 
encoding steps and therefore scan time. Sensitivity encoding (SENSE) is a parallel 
imaging technique which reduces the k-space sampling density by exploiting the known 
spatial sensitivity profiles of multiple receiver coils. Allowing more rapid spatial encoding 
(10,14). A reduction factor R defines the amount of k space sampling density (15), for 
example R=3 represents a three times reduction in the number of phase encoding steps. 
The fully sampled data information is then algorithmically reconstructed from the under 
sampled data from each coil and the corresponding sensitivity and noise profiles (10,14). 
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SENSE can be easily incorporated within any existing MRSI pulse sequence which is an 
advantage over other fast techniques as any pulse sequence related SNR losses can be 
avoided (10). There are associated SNR losses for SENSE with increasing reduction 
factors, but spatial resolution is theoretically preserved (15). 
2.2.7.4 Echo Planar Spectroscopic Imaging (EPSI) 
EPSI was first proposed by Mansfield et al in 1984 (16) with its use in the brain first 
adapted by Posse et al (17). An oscillating read gradient is applied during the readout 
(Figure 2-10). One-dimensional spatial encoding can therefore be acquired in a single 
shot, as each time domain data point corresponds to one lobe of read gradient. To extend 
into 2-dimensions an additional phase encoding loop is applied. This ultimately reduces 
the phase encoding steps by one dimension and therefore the acquisition time is 
drastically reduced.   
 
Figure 2-10 EPSI Sequence 
A few disadvantages of this technique are: technical problems can arise due to the stress 
the rapidly oscillating read gradient puts on the gradient system. Ghosting (spurious 
echoes) can also be observed due to imbalances in the positive and negative lobes within 
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the read gradient/ due any off-resonance effects. The latter can be compensated through 
the separate processing of the positive and negative lobes. However, this creates a 
reduction in spectral bandwidth (18).  
2.3 Magnetic Resonance Spectroscopy Analysis 
2.3.1 Fitting Methods: Modelling of MRS data 
MRS fitting methods can be categorized into three sections: black box, peak fitting and 
basis sets. Black box methods use either Linear Predictive Singular Value Decomposition 
(LPSVD) (19) or Hankel Singular Value Decomposition (HSVD) (20) which do not require 
any additional spectral information. However, because of this these methods struggle to 
fit complex data, where additional knowledge of spectral features is needed. This model 
also assumes a lorentzian lineshape which is rarely valid. 
Peak fitting methods such as AMARES (21), which model metabolite peaks individually, 
allow more prior knowledge to be introduced into the fitting model. Therefore, peak fitting 
models are more successful at fitting data with a higher complexity compared to black 
box methods.  
The spectral information acquired for short echo is more complex containing more 
metabolite peaks compared to longer echo times, as lower metabolite signals will have 
decayed at longer TE. To model these individually would be too labour intensive. The 
introduction of metabolite basis sets to the fitting model, as utilised by LCmodel (22) and 
Totally Automatic Robust Quantitation in NMR (TARQUIN) (23), is much more sufficient 
for the modelling of complex short TE spectra. LC model models the data within the 
frequency domain modelling the data as a linear combination of metabolite, lipids and 
macromolecule; accounting for the baseline signals through the use of smoothing splines.  
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TARQUIN was chosen to fit the spectral data within this thesis due to its ability to model 
complex short TE spectra. TARQUIN is a fully automatic software which models the data 
using a parameterized basis set of metabolites, lipids and macromolecules within the time 
domain. Time domain truncation removes baseline interference and uses constraints, 
such as non-negative metabolite quantities. These are enforced to improve reliability. In 
order to estimate signal amplitudes a non-negative least squares projection is used. Lipids 
and macromolecules are included in the basis set in order to impose soft constraints on 
the least squares projection, with the aim to reduce overfitting errors. In order to model 
spectral features the TARQUIN algorithm consists of three main stages: preprocessing, 
basis set simulation and finally the solution of the non-linear least squares problem. In 
pre-processing, residual water is removed by modelling the signal and its subsequent 
removal via subtraction from the FID. A zero-order phase correction is also applied in this 
stage in order to make visual inspection of spectra easier. Finally, automatic referencing 
is applied to make sure the water signal resonates at the center of the spectrum (24). For 
basis set simulation, metabolite components are simulated in TARQUIN using chemical 
shift and J coupling values from Govinderaju et al (25). A solution is then generated using 
the non-linear least squares projection. More details of these stages can be found in the 
following paper by Martin Wilson et al (24).    
2.3.2 Macromolecular Analysis Schemes: Modelling Macromolecular 
Contributions 
Macromolecular (MM) signals (their origin explained in section 2.4.9) have a significant 
contribution in short TE spectra which overlap the metabolite resonances. At longer TE 
the MM signal is reduced, due to shorter T2 relaxation times compared to the metabolite 
signals. If its contribution is not accounted for effectively error can be introduced into the 
fitting of short TE spectra. A number of methods have been proposed which either 
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decrease the MM contribution or to characterize it and include it within the fitting model. 
Increasing the echo time (TE) of the MRS acquisition will decrease these background 
signals. This method takes advantage of shorter MM T2 relaxation times found for 
compared to metabolites (26) due to their smaller molecular weight (27,28). However, at 
longer TE’s there is an inherent reduction in metabolite signal to noise ratio (SNR) due to 
T2 relaxation. Complex dephasing of multiplets can also reduce quantitation accuracy. 
The measurement of multiplets and lower SNR metabolites may therefore be more 
effective for short-TE acquisitions. 
MM analysis schemes have been developed to help characterize the MM signals and 
account for them in the fitting model. (28), with the view to improve the reliability of 
metabolite estimates. The inclusion of individually simulated macromolecule and lipid 
components within the analysis basis set  is currently the most common method  used to 
account for the MM contribution (29). These features can be obtained through the 
parameterization of metabolite nulled spectra. Seeger et al (29) parameterized the 
macromolecules by fitting an average MM spectrum to four broad lines which included 
the main MM resonances 1-7. Subsequently they can be introduced as prior knowledge 
into the spectral fitting. The MM signal can also be experimentally acquired using an 
inversion recovery (IR) sequence (27) since metabolite signals can be nulled at inversion 
time (TI) due to shorter MM T1 relaxation. Any residual metabolite peaks can be removed 
in post processing. 
2.3.3 Absolute Concentrations 
A number of methods have been proposed for the calculation of absolute metabolite 
concentrations. The most common being: (i) reference to water which acts as an internal 
standard (ii) reference signal to an external standard (iii) principle of reciprocity signal 
calibration (30).  
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The most common method (i) obtains absolute concentrations by referencing the 
metabolite signal to the signal obtained from water which acts as an internal standard 
(31–33).  This assumes the water content within the tissue which can be inaccurate for 
unknown diseases and within focal lesions. Water content also differs between Cerebral 
Spinal Fluid (CSF), grey and white matter but this can be accounted via segmentation. 
An unsuppressed water spectrum is acquired as well as the metabolite suppressed 
spectra within the same session. Its use for SVS has been effective as there is a minimal 
increase in scan time (<20s) and therefore can be applied in routine clinical practice. 
However, for MRSI the acquisition time becomes significantly longer due to the increased 
number of phase encoding steps, vital for spatial localisation, that are needed for both the 
metabolite and water reference data. This may preclude absolute quantitation of MRSI 
data for routine clinical use. 
2.4 Metabolites, Lipids and Macromolecules 
As seen in Figure 2-11, the spectral signal obtained from the brain is comprised of 
multiple metabolites, Macromolecule and Lipid resonances. A number of these have 
been proven to be useful in the diagnosis and prognosis of disease. The following 
section details the function, frequency and their use as biomarkers for disease for a 
range of spectral components.  
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Figure 2-11 Example healthy brain fitted spectra shown in red, with separation of 
individual metabolite peaks, macromolecules (MM) and lipids (Lip) from the fit. 
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2.4.1 NAA  
The most prominent N-acetyl aspartate (NAA) signal resonates at 2.01ppm and is the 
largest metabolite signal found within a healthy brain spectrum. N-acetyl aspartyl 
glutamate (NAAG), an unresolved contribution, can also be found at 2.04ppm. These are 
often combined to form total NAA (tNAA). Additionally, the aspartyl group also has a 
strongly coupled pH sensitive resonance ~2.6ppm. NAA is considered to be a neuronal 
“marker” and is exclusively located within the neurons, axons and dendrites of the central 
and peripheral nervous system. Its levels have been found to be reduced in pathologies 
associated with neuronal loss, for example brain tumours. Although observations of 
dynamic changes in neuronal concentrations indicate changes in NAA levels may also 
reflect neuronal dysfunction (34). In MRS it has been found to be a useful biomarker of 
neuronal integrity/density (10). NAA concentrations can vary between regions with higher 
concentrations observed in grey matter (~8-11mM) when compared to white matter (~6-
9mM) (35).  
2.4.2 Creatine 
Creatine is a methyl resonance at 3.03ppm that is involved in energy metabolism as ATP 
is generated through the creatine kinase reaction. This peak consists of both creatine and 
phospho-creatine contributions to form total Creatine (tCr). A second resonance at 
3.91ppm can also be observed originating from the CH2 component of creatine, provided 
it has not been saturated due to the water suppression pulses. Creatine levels within 
normal brain have been shown to vary between regions with lower concentrations found 
for white matter (5.3-5.7mM) when compared to grey matter (6.4-9.7mM). 
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2.4.3 Choline 
The choline peak can be found at 3.20ppm and is comprised of glycerophosphocholine 
(GPC) and phosphocholine (PC) and free choline. The combination of these is often 
referred to as total Choline (tCho). Choline plays a role in the synthesis of membranes 
and also their degradation. In disease states such as brain tumours elevated levels have 
been found to be a marker of membrane turnover. Within normal brain higher levels have 
been observed in white matter than in grey, with increased concentrations also found 
within specific regions of the brain such as the thalamus. The concentration of tCho in 
normal brain has been found to be approximately 1-2mM (36).  
2.4.4 Glutamate, Glutamine and Glx 
Glutamate (Glu) is a neurotransmitter and the most abundant amino acid within the brain. 
When neuronal excitation occurs, glutamate is released and diffuses across the neuronal 
synapse. It is then taken up by astrocytes and converted to glutamine (Gln). For studies 
at 1.5Tesla, Glu and Gln are often combined to create a Glx peak due to their strong 
overlap at this field strength. Their main resonance is at 3.7ppm however multiplet peaks 
do occur between 2.1 and 2.4ppm. Glx is typically assigned from the latter due to strong 
overlap of signals at 3.7ppm. At 3 Tesla and higher fields Glu and Gln can be separated 
more effectively and measured more accurately. Average Glu concentrations ranges from 
6 to 12.5mM and 2 to 4mM for Gln (26).    
2.4.5 Myo-inositol 
Myo-inositol (Ins) resonates between 3.5 and 3.6ppm and is one of the higher signals 
observed in short echo time spectra. It is a pentose sugar which is involved in cell 
messenger systems. Elevated levels have been observed in diseases such as 
Alzheimer’s (37–39) and altered levels observed in brain injury (40–42). 
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2.4.6 Taurine 
Taurine comprises of two triplet peaks centred at 3.25ppm and 3.42ppm. Its exact function 
is poorly understood but it has been proposed that it acts as an osmoregulator and 
modulator for neurotransmission. In healthy human brain its concentration is found to be 
approximately 1.5mM  (34).  
2.4.7 Glutathione 
Glutathione, in its reduced form (GSH) is formed of a tripeptide consisting of glycine 
(3.77ppm singlet), cysteine (three doublets of doublets 2.93, 2.98 and 4.56ppm) and 
glutamate (3.77ppm doublet of doublets and multiplets at 2.15 and 2.55ppm) (26). It can 
be found within the brain with concentrations between 1-3mM in healthy tissue (43–45). 
GSH is an antioxidant which maintains normal red blood cell structure and maintains 
haemoglobins ferrous state. It also acts as an amino acid transport system and is a 
storage form of cysteine (45). Interest in GSH has been found for studies of Parkinson’s 
disease and neurodegenerative diseases within the basal ganglia (46,47). 
2.4.8 Lactate 
The doublet Lactate peak can be found at 1.3ppm and is a marker of cell death and 
necrosis. It is the end product of anaerobic glycolysis and is present at low concentrations 
within the brain (48). Increased levels are observed in conditions where blood flow is 
restricted for example in ischemic stroke (49–51) and tumours (5,52). Its spectral 
appearance varies between echo times; at longer echo time (TE=144ms) the lactate 
peaks are inverted and therefore can be effectively separated from overlapping lipid 
signals which also will have decayed away due to its shorter T2 (52,53).  
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2.4.9 Lipids and Macromolecules 
Mobile lipid resonances can occur around 1.3ppm. Their observation in brain tumours is 
well known and can be indicative of malignancy and used for predicting survival (1,54,55). 
Lipids have also been observed in stroke (56) and multiple sclerosis (57–59) patients. 
MM signals are broad signals and have been attributed to the methyl and methylene 
resonances in cytosolic proteins (60). Approximately 10 main MM resonances can be 
observed (Figure 2-12): M1 (0.93 ppm), M2 (1.24 ppm), M3 (1.43ppm), M4 (1.72ppm), 
M5 (2.05 ppm), M6 (2.29ppm), M7 (3.00 ppm), M8 (3.20 ppm), M9 (3.8-4.0ppm) and M10 
(4.3ppm).   
 
Figure 2-12 Example healthy volunteer MM spectra with main 10 MM components 
highlighted 
 
The MM signal can be extracted as shown in Figure 2-12 using the inversion recovery 
(IR) technique (61). The metabolite signal can be nulled at a particular inversion time (TI) 
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due to differing T1 relaxation times. Due to their short T1, lipid contributions can also be 
found within the metabolite nulled spectra.  
The MM content itself can provide useful clinical information for various diseases. For 
example, altered MM levels have been observed in both stroke (62,63) and brain tumours 
(52).   
2.5 Data Quality, Issues and Artefacts 
As stated previously the data quality of MRS can be variable this can arise for various 
reasons and quality control measures have to be defined. A number of which are 
discussed within this section. 
2.5.1 Signal to Noise Ratio 
Signal to Noise Ratio (SNR) can be defined in frequency domain (FD) as the height of the 
largest peak/root mean square (rms) amplitude of the noise in signal free part of the 
spectrum. Low SNR can become a problem particularly in determining low concentration 
metabolites as their peaks can become indistinguishable from the noise introducing error 
into metabolite estimations. A number of things can be done to prevent low signal to noise; 
SNR is proportional to the VOI size, therefore a larger VOI or voxel size will achieve a 
better SNR. However increased voxel sizes will also reduce the sampling resolution as 
fewer spectra can be acquired within the VOI. The optimisation of hardware can also help 
improve SNR. For example, the use of phased-array head coils. Acquiring more signal 
averages will also provide better SNR due to its proportionality to the square root of the 
number of acquisitions. However more signal averages will result in the extension of scan 
time which may prove disadvantageous in clinic. Therefore, careful consideration is 
needed for SNR optimisation. 
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2.5.2 Line width 
Line width is determined as the full width at half maximum (FWHM) of the peak height in 
FD (Figure 2-13). The line width represents the attainable resolution available to discern 
between spectral peaks. Metabolite peaks will start to overlap with increasing FWHM 
resulting in poorly defined spectra, line width therefore is a useful tool for the rejection of 
poor MRSI data. As fitting models can rely heavily on line width an increase in FWHM can 
introduce error into the fitting estimates. 
Shimming is a method that adjusts the field gradients in order to improve the magnetic 
field homogeneity across a voxel. Spectral resolution can be improved by using higher 
order shims in order to obtain better shimming across the VOI, by using a smaller VOI or 
by moving the VOI away from tissue interfaces. 
 
Figure 2-13 Illustration demonstrating how the Line width (FWHM) is determined 
from a spectral peak (water line width in this instance) 
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2.5.3 Statistical Methods 
2.5.3.1 Precision and Accuracy 
The precision of a measurement system is the degree to which repeated measurements 
undertaken in identical conditions can reproduce the same result. Closely related to 
precision is the parameter reproducibility. A measure of reproducibility is needed in order 
to define normal ranges; it can be used to highlight systematic and random error in order 
establish how robust a technique is. Overall reproducibility can be determined using 
Coefficients of Variance (COV’s) defined as the ratio of the standard deviation and mean 
across the samples. This particular measure can be useful in indicating how reliable a 
particular method is, allowing normal ranges to be established and new protocols to be 
validated. Accuracy relates to how well a method can produce the true value. The ability 
of a method to extract the correct values for example, expected metabolite 
concentrations, must be investigated to ensure that the correct information is extracted 
as any error may lead to false interpretation. Therefore, comparisons to normal values 
are needed in combination with a test for robustness in order to assess a techniques 
performance.   
2.5.3.2 Bland Altman Statistics 
The introduction of new protocols for a particular measurement often requires a validation 
to be carried out against the already established “old” method. Assessment is required to 
establish whether the new technique can offer improvement whilst minimizing the 
measurements variation from the “old” method. The variation between them needs to be 
low enough in order to replace the current technique with the new one. Correlation 
coefficients (r) measure the strength of a relationship between two measurements but do 
not test how well they agree. The use of Bland-Altman statistics allows the agreement 
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between two methods to be measured using graphical techniques and simple equations 
(64).  
A plot of difference versus the mean of the two methods allows you to determine the 
relationship between measurement error and establish any bias from the true value. As 
the true value cannot be easily established, the mean provides a good estimate. The 
mean difference is calculated in order to estimate bias and the spread of the data 
(standard deviation of the differences). Figure 2-14 shows an example of a Bland-Altman 
plot taken from chapter 4 which compares the water amplitude measurement with the 
new proposed method SENSE R=3 and the full acquisition data SENSE R=1 (old method) 
in this case. 
 
Figure 2-14 Example Bland Altman Plot used to estimate bias and assess the 
agreement between two methods (σ is defined the standard deviation) 
 
The mean difference line indicates the bias caused by systematic differences between 
the two methods. For Figure 2-14 the points show a randomly distributed error. The 
majority of points also lie within the 2σ cut-off; therefore, it can be concluded that there is 
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good agreement is shown between these two methods, provided the standard deviation 
is low enough to be deemed acceptable. 
2.5.5 Chemical Shift Artefact 
Volume selection methods, e.g. PRESS, rely on frequency encoding to selectively excite 
spins resonating at the Larmor frequency located within the VOI only. However, 
metabolite signals with different chemical shifts i.e. resonances will experience different 
slice selections. Thus, the VOI experiences a shift in location between differing 
metabolites. Slice selection is defined by the RF pulse bandwidth, the chemical shift ω0 
of the metabolite of interest and the selective gradient strength. Therefore, the amount 
the VOI is displaced is dependent on these parameters. The effect of this shift increases 
with field strength (30,65). To minimise the voxel shift it has been suggested that the 
transmit frequency be set to the middle of the spectral region of interest (found to be 
2.5ppm for water suppressed data and on the water resonance for unsuppressed) (30).  
2.5.6 Point Spread Function and Outer Volume Signal Bleed Through 
Ideally RF excitation pulses would have a rectangular profile. However, in reality the RF 
slice selection is imperfect as a very long pulse duration is needed in order to obtain sharp 
slice profile. In order to achieve this the minimum TE would need to be increased, a 
compromise is needed.  This signal therefore does not necessarily reflect the original 
desired rectangular shape of the voxel of interest.  As these volume selection pulses are 
not completely optimal, unwanted spin contributions will be excited outside the VOI. 
Therefore, when the Fourier transform is applied to allow the original signal to be 
reconstructed the voxel will be contaminated with signals from adjacent regions/voxels. 
This is known as “Signal Bleed Through”.  This becomes a particular issue for outer 
volume lipids originating from the scalp which causes contamination within the spectra. 
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Therefore, effective lipid suppression techniques must be applied as detailed in section 
2.2.6. It is also worth noting that PSF also improves with higher resolution scans. 
Mathematically signal bleed through can be modelled using a point spread function (PSF) 
(12). Figure 2-15 shows an example PSF in 3-dimensions. Where position (X, Y, Z) = (0, 
0, Z) mm is the centre of the desired voxel and at increasing distance away from this point 
describes the influence of outer volume signals contributing to the overall voxel signal. 
 
Figure 2-15 Example PSF Function 
 
2.5.7 Water Suppression 
Due to the high level of water within tissue, if it is not suppressed effectively this can prove 
problematic in the determination of more downstream metabolite peaks such as myo-
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inositol. It can be accounted for in the data fitting/ post processing software, provided that 
the residual water is smooth and not large in comparison to the metabolite signal. 
However, dominating residual water peaks lead to sidebands and offsets being introduced 
to the spectra causing error in metabolite determination. Post processing methods can 
help minimize its impact but may result in the suppression/loss of metabolite information 
around this region.  
2.5.8 Movement 
Subject movement can cause a number of issues; repeated small motions e.g. respiration 
can cause an increase in line width, frequency shifts and reduced metabolite 
measurements due to phase cancellation maybe observed (66). If subject movement 
occurs during the spectroscopy sequence, it will result in the data being collected from 
the wrong location. This can be observed as a doubling of all peaks i.e. single peaks will 
appear as double peaks (30). In MRSI movement also causes spatial blurring where 
metabolite signals will be observed outside the head (67). For the spatial localisation of 
metabolite signals it is important that the subject remains still throughout the scan session, 
this can prove difficult in long acquisitions.  
2.6 Conclusion 
1H MRSI has proven to be a useful technique in the diagnosis and prognosis of disease 
within the brain. However, developments in both the acquisition and analysis of this 
technique are needed in order to ease its implementation into routine clinical use. Long 
acquisition times and variable data quality all preclude its use. Developments in new 
protocols that act to speed up scan time, expand the sampling volume e.g. 2D to 3D 
and improve data quality need to be fully validated before their clinical use in order to 
assess their efficacy.
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3. Influence of Macromolecule Baseline on 1H MRSI Reproducibility 
3.1 Introduction 
Macromolecular (MM) signals are broad resonances which overlap with metabolites of 
interest. Error can be introduced into the spectral fitting model if their contributions are 
either (i) removed or (ii) characterised incorrectly. An increase in echo time will 
decrease the MM contribution during the acquisition due to shorter T2 relaxation times 
compared to their metabolite counterparts. The use of macromolecular analysis 
schemes (simulated and experimentally acquired) in the fitting model have also been 
proposed to account for the MM signals in the fitting (28). A recent study by Karim 
Snoussi et al (68) found no significant differences between MM signals in white and 
grey matter regions of the brain, implying the use of a single MM baseline spectra could 
be sufficient to include in a basis set for the fitting of spectra from multiple brain regions. 
MRS reproducibility studies are vital in order to assess the reliability of imaging 
protocols for their optimization. A number of reproducibility studies in MRS exist within 
the literature; covering a large range of echo times, field strengths and techniques (69–
75). A recent study by Danesh K.Deelchand et al combined an experimental baseline 
with single voxel 1H MRS (SVS) for two sites within the brain and found highly 
reproducible neurochemical profiles could be achieved between scanners and regions, 
providing optimized protocols were kept consistent (74). Previously comparisons have 
been made between the use of simulated baselines and experimental baselines in the 
fitting of spectra (76–78); however their effect on the reproducibility of 2D 1H MRSI 
data has not previously been evaluated. In this study two types of MM schemes: 
simulated Si.BL and experimentally acquired Ex.BL and three echo times (35, 80 and 
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144ms) and their effect on the short term 1H MRSI data reproducibility at 3Tesla have 
been investigated to aid in protocol design for future clinical studies. The following work 
has been peer reviewed and published as a full paper in the Magnetic Resonance in 
Medicine Journal (7). 
3.2 Methods 
All MR scanning was performed on a 3 Tesla Philips Achieva TX MR system with a 
32-channel head coil at Birmingham Children’s Hospital, UK. All volunteers who 
participated in the study gave their informed consent under full ethical approval. 
3.2.1 MRSI data collection 
2D MRSI data was collected from 8 healthy volunteers (aged 23-30). An initial 3D T1 
weighted anatomical MRI reference scan was obtained for MRSI grid positioning. All 
MRSI grids were manually placed for two regions A) above the Corpus Callosum (3 
volunteers), see figure 3-1A and 3-1B and B) level with the Basal Ganglia (5 
volunteers), see Figure 3-1C and 3-1D, with the following acquisition parameters: Field 
of View (FOV) matrix size 15x13 voxels; voxel size 13mm x 13mm x 13mm; TR=2s. 
Pencil beam shimming was applied. Data was collected at three different echo times 
on separate volunteers: TE=35ms (region: A=1 and B=2 volunteers), TE=80ms 
(region: A=1 and B=1 volunteer) and TE=144ms (region: A=1 and B=2 volunteers). 
PRESS localization was used to excite a 6x6 voxel volume of interest (VOI) (78 mm x 
78 mm x 13 mm) fixed centrally to the FOV; corresponding to a fully excited 5x5 voxel 
region with a ½ voxel margin around the PRESS excitation region, edge voxels were 
discarded in post processing and the VOI extracted via a water signal threshold. In 
order to assess short term reproducibility all scans were acquired in triplicate without 
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grid repositioning; reshimming and water suppression frequency optimization in 
between scans was performed if deemed necessary. Due to lengthy scanning times, 
different volunteers were scanned for each echo time and region. Absolute 
concentrations were obtained by collecting water unsuppressed data during the first 
scan for each volunteer using the same scanning parameters as the suppressed 
(metabolite) data collection.  
 
 
Figure 3-1 Example healthy volunteer MRSI grid placement for: above the 
Corpus Callosum (A) sagittal view and (B) axial view and the Basal Ganglia (C) 
sagittal and (D) axial view. Water line width (FWHM) maps overlaid for (B) 
Corpus Callosum and (D) Basal Ganglia for the PRESS box 
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3.2.2 Spectral Fitting 
All spectral analysis was performed using the TARQUIN software package (23). The 
simulated macromolecular analysis scheme (Si.BL) used the following basis set to fit 
the MRSI data comprised of 16 individually simulated components: Alanine (Ala), 
Aspartate (Asp), Creatine (Cr), -CrCH2, Gamma-aminobutyric acid (GABA), Glucose 
(Glc), Glutamine (Gln), Glutathione (Glth), Glycerophosphorylcholine (GPC), Myo-
inositol (Ins), Lactate (Lac), Lipid peaks at 0.9, 1.3a, 1.3b and 2.0ppm, Macromolecules 
at 0.9, 1.2, 1.4 and 2.0ppm, N-Acetyl-Aspartate (NAA), N-Acetyl-Aspartateglutamate 
(NAAG), Phosphorylcholine (PC), Phospho-creatine (PCr), Scyllo-inositol (s-Ins), and 
Taurine (Tau). All metabolite components were simulated in TARQUIN using chemical 
shift and J coupling values from Govinderaju et al (34). The simulated macromolecular 
signal is taken to be the combination of the individual macromolecular and lipid 
component as listed in Table 1 of the paper describing the TARQUIN algorithm (24). 
3.2.3 Experimental Baseline Model Derivation (Ex.BL) 
A Single Voxel Spectroscopy (SVS) inversion recovery sequence was used to acquire 
metabolite nulled data for improved macromolecular determination 
(TE/TR=35/2500ms PRESS excitation). An initial experiment was performed (data 
presented in section 3.3.1) to establish the optimal inversion time for metabolite signal 
nulling. Spectra were acquired for TI=500,650 to 850ms in 50ms steps and an optimal 
TI=750ms was determined. SVS inversion recovery data was collected from 7 healthy 
volunteers (aged 23-30) from left and right parietal white matter regions. Ten voxels 
were chosen across the 7 volunteers due to their high spectral quality i.e. free from 
artefacts caused by spurious echoes and inefficient water suppression. These data 
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were then compiled to create an average MM spectrum. The average spectrum was 
subsequently fitted using TARQUIN to obtain a noise free model of the macromolecular 
baseline. A macromolecule basis set composed of Gaussian peaks was initially 
constructed based on known peak positions and visual inspection. This basis set was 
fit to the average spectrum allowing peak amplitudes, widths and frequencies to be 
optimized. The basis set was then updated with the newly determined frequencies and 
peak widths and this process of basis set refinement was repeated until fitting resulted 
in negligible adjustment to the basis set (Table 3-1). In addition to macromolecular 
signals, narrow metabolite signals for NAA, NAAG, TCho, TCr and TCrCH2 were also 
included in the basis set to account for metabolite signals that were partially nulled 
(Figure 3-2). The fitted residual metabolite signals contributions were removed (via 
subtraction) in post processing to obtain the MM contribution only. Finally, the 
optimized macromolecule peaks (excluding residual metabolite signals) were summed 
and added to a basis set of metabolite signals (described above) – replacing the 
individual macromolecular and lipid components. Analysis using this experimentally 
derived baseline model will be referred to as Ex.BL. 
3.2.4 Data analysis  
MRSI spectra exported from the scanner workstation in DICOM format were imported 
into TARQUIN. Spectra were fitted with two different basis sets: one including the 
Ex.BL and another that models the MM baseline using a set of individually simulated 
macromolecular resonances (Si.BL). Subsequent data analysis was performed using 
Python programming language. Metabolite coefficients of variance (COV) were 
calculated as the voxel wise ratio of the standard deviation and mean for each 
volunteer and TE over the three MRSI acquisitions. COV’s were then grouped 
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according to echo time, irrespective of region, and a mean COV for each metabolite 
calculated. This was performed to avoid regional bias with respect to data quality. A 
zero fill with a k space factor of 2 was used to improve the spatial resolution and 
number of voxels available for analysis. The VOI was extracted via a water amplitude 
threshold of >50% of the maximum water amplitude, and only voxels with a water line 
width <0.1 ppm (12.8Hz) were analyzed. A total number of voxels of 200/324, 198/230 
and 246/246 were extracted for TEs = 35, 80 and 144ms respectively with this line 
width threshold. For analyses in section 3.3.4 the total number of voxels for line width 
criterion 0-0.06ppm were 94, 54 and 158 for TE=35, 80 and 144ms respectively. For 
line width criterion 0.06-0.1ppm the total number of voxels were 106 for TE=35ms, 144 
for TE=80ms and 88 for TE=144ms. For a water line width criterion of 0.1-0.15ppm 70 
voxels were found for a TE=35 and 32 for a TE = 80ms.   Water line width was defined 
as the full width half maximum FWHM of the unsuppressed water peak in frequency 
domain. The unsuppressed water peak was taken to be our measure of data quality 
due to its robustness in comparison with metabolite line width - which can become 
unstable with noise and artifacts. We also assume that the water line width is directly 
correlated with metabolite FWHM, and therefore can be used as a proxy for data 
quality. Metabolite COV’s were calculated to assess technical reproducibility for 
TE=35, 80 and 144ms comparing the two macromolecular analysis schemes: 1) Ex.BL 
and 2) Si.BL. COV’s for the following metabolites were evaluated: total N-Acetyl 
Aspartate (tNAA), total Creatine (tCr), total Choline (tCho), Glutamate (Glu), Glutamine 
(Gln), Glutamate + Glutamine (Glx), Taurine (Tau), Glutathione (Glth) and myo-inositol 
(Ins).  A One-Way Analysis of variance (ANOVA) test was performed for the metabolite 
COV’s to test if a difference between the three data sets from TE=35, 80 and 144ms 
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were significant (degrees of freedom between groups = 2). For each volunteer, the 
voxel wise mean was calculated across the three scans. The mean voxel COV values 
were then grouped according to echo time and an overall mean COV calculated for 
each echo time. All statistical tests were performed on these resultant COV’s for each 
metabolite. For this study, each mean voxel COV was considered to be independent 
from each other. Subsequent unpaired t-tests were carried out to assess the statistical 
significance of any differences in reproducibility in comparison with TE=80ms, those 
with p<0.05 were deemed significant. For this chapter, in consistence with the current 
literature the P-value was chosen to show any statistically significant differences. The 
degrees of freedom have been calculated for each test in order to express by how 
much the values can vary.  These values have been chosen to highlight any 
significance in results, as due to the large quantity of data expressed within this study 
and to be consistent with studies of this nature, they have been chosen for ease of 
interpretation.  
Average white matter metabolite concentrations were also calculated to validate 
quantitation methodology. Metabolite concentrations were measured from white matter 
voxels selected using the axial T1 anatomical image registered to the MRSI grid. 
Average metabolite concentrations for 36 white matter voxels were taken from the slice 
going through the Corpus Callosum (12 from each scan) for TE=35, 80 and 144ms (3 
volunteers total). This was done for both Si.Bl and Ex.Bl MM analysis schemes and a 
percentage difference in concentration was calculated between these two fitting 
methods. T2 relaxation correction was applied assuming a T2 of water of 60ms and 
metabolite T2 of 200ms. 
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This analysis focused on the average across voxels in order to ease the ability to make 
direct comparisons between subjects and literature values. Although an advantage of 
MRSI is the increase in spatial specificity for individual cases, when comparing multiple 
subjects’ due to the large amount of data acquired an average comparison is more 
suitable. 
3.3 Results 
3.3.1 Experimental Baseline Acquisition 
In order to determine the optimum inversion time (TI) for nulling the metabolite signals 
a SVS inversion recovery sequence was used. Spectra were acquired for TI=500 and 
650 to 850ms in 50ms intervals (Figure 3-2).  
Figure 3-2 shows the inversion recovery spectra for the above TI’s. For this TI range 
the metabolite signal can be seen to go from positive to negative in magnitude. An 
optimal inversion time of 750ms was determined as it was most efficient at nulling the 
metabolite signal containing the lowest metabolite signal contributions and no negative 
signal contributions. Subsequently SVS inversion recovery data (TI=750ms) was 
collected from 7 healthy volunteers (aged 23-30) from left and right parietal white 
matter regions. Ten out of fourteen volunteer voxels were chosen for further analysis 
due to their high spectral quality, voxels were excluded which contained artefacts or 
distortions that overlapped with the MM spectral contributions. Consistent MM content 
was found i.e. good overlap of spectral features between all voxels across the 
volunteers was observed (Figure 3-3). 
The resultant mean MM spectrum was determined across the ten voxels and fitted 
using a MM basis set (see section 3.2.3) in TARQUIN to obtain a noise free model of 
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the MM baseline and is shown in Figure 3-4, the basis set and its properties split into 
its 13 components can be viewed in Table 3-1. Within the literature, 10 main 
resonances have been identified and therefore contributions are grouped and named 
as M1 to M10 (Figure 2-12). As we identified 13 contributions within our acquired MM 
model we have therefore named these contributions according to their chemical shift 
e.g. MM 40 is positioned at 4.0PPM.  
The optimised MM peaks with the exclusion of the residual metabolite peaks (removed 
in post processing) were then summed and added to a basis set of metabolite signals 
to form the experimentally acquired baseline model Ex.BL.  
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Figure 3-2 Inversion Recovery Spectra for inversion time (TI) for a range 500-
850ms 
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Figure 3-3 Spectral Overlap of Inversion Recovery Metabolite Nulled Spectra 
TI=750ms for 10 volunteer voxels 
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Figure 3-4 Mean Ex.BL MM Spectra taken from 7 healthy volunteers split into 
its MM and residual metabolite components. MM contributions within our 
Ex.BL MM model are labelled according to their Chemical shift e.g. MM40 is at 
4.0PPM. 
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Table 3-1 The Ex.BL broken down into its thirteen MM components detailed 
according to Amplitude (AU), PPM and FWHM (Hz). 
Name Amplitude 
(AU) 
Freq (PPM) FWHM (Hz) 
MM09 0.72 0.90 21.20 
MM12 0.28 1.21 19.16 
MM14 0.38 1.38 15.90 
MM16 0.05 1.63 7.50 
MM20 0.45 2.01 29.03 
MM21 0.36 2.09 20.53 
MM23 0.36 2.25 17.89 
MM26 0.04 2.61 5.30 
MM30 0.20 2.96 14.02 
MM31 0.11 3.11 17.89 
MM37 0.64 3.67 33.52 
MM38 0.07 3.80 11.85 
MM40 1.00 3.96 37.48 
 
3.3.2 Impact of Echo Time on and Ex.Bl on spectral fitting 
It can be seen from Figure 3-5A and 3-5B that the inclusion of a better-defined MM 
model Ex.BL, reduces the level of the broad background signals (obtained from a 50-
point moving average filter of the fit residual) compared to Si.BL for the fitting of short 
TE spectra. A reduction in MM content relative to the metabolite signals was also 
observed via an increase in echo time to 80 and 144ms (Figure 3-5C and 3-5D) due 
to shorter T2 relaxation times. A reduction in SNR is also observed within increasing 
echo time due to T2 relaxation effects and the dephasing of metabolite multiplets. 
 52 | P a g e  
 
 
 
Figure 3-5 Example healthy volunteer spectra split into four components: Data, 
Fit, MM analysis scheme (Si.BL or Ex.BL) and residual background signal for 
TE's: A) TE=35ms (Si.BL); B) TE=35ms (Ex.BL); C) TE=80ms (Si.BL) and D) 
TE=144ms (Si.BL) 
3.3.3 The Effect of Echo Time and Macromolecular Analysis Schemes on 
Reproducibility 
Coefficients of Variance (COV’s) were calculated for voxels containing spectra that 
meet the line width value criteria <0.1ppm (Table 3-2). Overall, for both Si.BL and 
Ex.BL MM analysis schemes, COV’s across the three echo times 35, 80 and 144ms 
were found to be statistically different via an ANOVA test for the following metabolites: 
tNAA, tCr, Glu, Gln, Ins, Glth and Tau (p<0.00001). An echo time of 80ms was found 
to provide the most reproducible metabolite estimates for tNAA, tCho and tCr with 
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COV’s<9%. Additionally, a TE of 80ms showed improved reproducibility, for both MM 
analysis schemes, compared to TE=35ms (p<0.01) for the following five metabolites: 
tNAA, tCr, Gln, Glth and Tau (Table 3-2).  
Table 3-2 Metabolite Coefficients of Variance (COV’s) for TE=35, 80 and 144ms 
for voxels containing spectra that meet the overall water line width criteria of 
between 0 and 0.1ppm showing significant (p<0.05) differences from an 
unpaired t-test between Si.BL and Ex.BL for TE=35ms (†), TE=80ms (‡) and 
TE=144ms (¥). Significances of p<0.01 are denoted as: TE=35ms (††), TE=80ms 
(‡‡) and TE=144ms (¥¥). ANOVA degrees of freedom within groups= 641. 
Line width 0-0.1ppm 
  TE=35ms TE=80ms TE=144ms 
Echo time 
comparison 
 Metabolite 
Coefficient of 
Variance % 
Coefficient of 
Variance % 
Coefficient of 
Variance % ANOVA 
 Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL 
tNAA††¥¥ 9.99 7.56 6.03 5.35 12.31 7.81 <0.00001 <0.00001 
tCr 10.13 9.25 7.18 7.22 11.56 10.91 <0.00001 <0.00001 
tCho 9.00 9.40 8.16 8.10 9.78 9.61 0.1209 0.1027 
Glu†† 20.35 16.33 22.36 22.82 45.96 47.57 <0.00001 <0.00001 
Gln¥ 83.80 88.85 56.22 60.19 47.37 53.22 <0.00001 <0.00001 
Glx††¥ 24.85 19.95 22.81 23.25 22.49 25.39 0.1525 0.0001 
Ins 15.36 15.36 16.97 17.87 34.46 33.84 <0.00001 <0.00001 
Glth† 48.43 68.14 28.33 27.67 69.06 68.39 <0.00001 <0.00001 
Tau†† 127.97 89.93 70.56 70.56 70.71 66.25 <0.00001 <0.00001 
Note: Significant differences shown from an unpaired t-test between Si.BL and Ex.BL 
for TE=35ms (†), TE=80ms (‡) and TE=144ms (¥) †, ‡ and ¥ <0.05 and ††, ‡‡ and 
¥¥<0.01. 
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The most reproducible metabolites across with CoV’s< 13% for all echo times were 
found to be tNAA, tCr and tCho. Lower variation using the Ex.BL model at TE=35ms 
compared to TE=80ms was observed for Glu (p<0.01) and Glx (p<0.05), it is likely that 
this is the result of signal dephasing, therefore a short echo acquisition maybe 
preferred depending on metabolite of interest. The highest variation was found for long 
echo TE=144ms spectra with Ex.BL COV’s tNAA=7.81%, tCr=10.91% and 
tCho=9.61%; compared to 7.56%, 9.25% and 9.4%for TE=35ms and 5.35%, 7.22% 
and 8.1% for TE=80ms respectively (Table 3-2). Variation is significantly reduced with 
the use of an Ex.BL for TE=35ms compared to Si.BL for tNAA, Glu, Glx and Tau 
(p<0.01). However, a Si.BL provided significantly better reproducibility for the 
measurement of Glth (p<0.05).  
3.3.4 The Effect of Line Width and Macromolecular Analysis Schemes on 
Reproducibility 
Data quality, along with echo-time and analysis methods, can have a significant impact 
on MRS reproducibility. Therefore, voxels were stratified according to their line width: 
“good” 0-0.06ppm (Table 3-3); “acceptable” 0.06-0.1ppm (Table 3-4) and “poor” 0.1-
0.15ppm (Table 3-5) groups were identified to investigate the impact of line width on 
reproducibility. An improvement in COV of ~35% and ~22% for tNAA was observed 
between “good” and “acceptable” data for Si.BL and Ex.BL respectively.  
The use of an Ex.BL macromolecular analysis scheme found improved reproducibility 
for poorer line widths compared to the Si.BL analysis. Ex.BL analysis resulted in a 
large reduction in tNAA COV of 38% for “poor” line widths between 0.1 and 0.15ppm 
(Table 3-5). Smaller reductions of ~30% and ~15% were observed for acceptable 
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(0.06-0.1ppm) and “good” (0-0.06ppm) line widths respectively. For increasing echo 
time, improved reproducibility between Si.BL and Ex.BL was found for tNAA, tCr, tCho, 
Glx and Tau (Tables 3-3 and 3-4) – most likely due to a reduction in MM signal 
contribution at longer TE’s. 
Table 3-3 Metabolite Coefficients of Variance (COV’s) for TE=35, 80 and 144ms 
for voxels containing spectra that meet the “good” water line width criteria of 
between 0 and 0.06ppm showing significant (p<0.05) differences from an 
unpaired t-test between Si.BL and Ex.BL for TE=35ms (†), TE=80ms (‡) and 
TE=144ms (¥). Significances of p<0.01 are denoted as: TE=35ms (††), TE=80ms 
(‡‡) and TE=144ms (¥¥). ANOVA degrees of freedom within groups = 303. 
Line width 0-0.06ppm  
TE=35ms TE=80ms TE=144ms Echo time 
comparison 
Metabolite Coefficient of 
Variance % 
Coefficient of 
Variance % 
Coefficient 
of Variance 
% 
ANOVA 
 
Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL 
tNAA¥¥ 7.79 6.59 4.07 3.81 10.96 7.55 <0.00001 <0.00001 
tCr† 10.52 8.69 4.70 4.25 10.19 9.90 <0.00001 <0.00001 
tCho 8.16 8.19 5.91 5.75 9.16 8.81 <0.05 <0.05 
Glu†† 17.30 13.73 16.80 17.87 37.08 41.52 <0.00001 <0.00001 
Gln 83.98 93.24 41.61 46.79 46.91 52.31 <0.00001 <0.00001 
Glx†† 19.54 15.39 18.55 19.80 22.01 24.50 <0.05 <0.00001 
Ins 15.94 15.69 10.24 10.94 27.00 27.22 <0.00001 <0.00001 
Glth 33.08 38.41 27.34 25.37 62.60 61.22 <0.00001 <0.00001 
Tau†† 127.87 89.93 62.30 60.61 60.63 56.44 <0.00001 <0.00001 
Note: Significant differences shown from an unpaired t-test between Si.BL and Ex.BL 
for TE=35ms(†), TE=80ms(‡) and TE=144ms(¥) †, ‡ and ¥ <0.05 and ††, ‡‡ and  
¥¥<0.01. 
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Table 3-4 Metabolite Coefficients of Variance (COV’s) for TE=35, 80 and 144ms 
for voxels containing spectra that meet the “acceptable” water line width 
criteria of between 0.06 and 0.1ppm showing significant (p<0.05) differences 
from an unpaired t-test between Si.BL and Ex.BL for TE=35ms (†), TE=80ms (‡) 
and TE=144ms (¥). Significances of p<0.01 are denoted as: TE=35ms (††), 
TE=80ms (‡‡) and TE=144ms (¥¥). ANOVA test degrees of freedom within 
groups = 335.  
Line width 0.06-0.1ppm  
TE=35ms TE=80ms TE=144ms Echo time 
comparison 
Metabolite Coefficient of 
Variance % 
Coefficient of 
Variance % 
Coefficient of 
Variance % ANOVA  
Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL 
tNAA††¥¥ 11.94 8.41 6.77 5.92 14.73 8.27 <0.00001 <0.0001 
tCr 9.78 9.74 8.12 8.33 14.02 12.73 <0.00001 <0.001 
tCho 9.75 10.47 9.00 8.98 10.89 11.03 0.2815 0.1056 
Glu† 23.06 18.63 24.45 24.68 62.45 59.21 <0.00001 <0.00001 
Gln 83.65 85.64 61.78 65.36 48.18 54.81 <0.00001 <0.00001 
Glx† 29.56 23.99 24.41 24.54 23.34 26.99 0.01 0.3328 
Ins 14.85 15.06 19.49 20.47 47.85 45.72 <0.00001 <0.00001 
Glth† 63.00 102.50 28.71 28.53 92.26 88.03 <0.00001 <0.00001 
Tau†† 128.16 96.08 73.74 74.43 91.93 86.37 <0.00001 <0.01 
Note: Significant differences shown from an unpaired t-test between Si.BL and Ex.BL 
for TE=35ms (†), TE=80ms (‡) and TE=144ms (¥) †, ‡ and ¥ <0.05 and ††, ‡‡ and 
¥¥<0.01. 
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Table 3-5 Metabolite Coefficients of Variance (COV’s) for TE=35 and 80ms for 
voxels containing spectra that meet the “poor” water line width criteria of 
between 0.1 and 0.15ppm showing significant (p<0.05) differences from an 
unpaired t-test between Si.BL and Ex.BL for TE=35ms (†) and TE=80ms (‡). 
Significances of p<0.01 are denoted as: TE=35ms (††) and TE=80ms (‡‡). 
Degrees of freedom = 101 
Line width 0.1-0.15ppm 
  TE=35ms TE=80ms 
 Metabolite 
Coefficient of 
Variance % 
Coefficient of 
Variance % 
 Si.BL Ex.BL Si.BL Ex.BL 
tNAA††‡‡ 23.09 14.39 12.96 6.53 
tCr 15.53 14.92 10.21 10.22 
tCho 15.15 14.17 18.44 17.44 
Glu 30.62 27.46 44.72 40.21 
Gln 56.13 56.46 92.37 101.36 
Glx 23.99 23.75 42.56 38.28 
Ins 27.85 27.22 34.79 38.10 
Glth† 103.15 121.31 44.15 46.19 
Tau 141.42 131.06 73.90 77.15 
Note: Significant differences shown from an unpaired t-test between Si.BL and Ex.BL 
for TE=35ms (†) and TE=80ms (‡) † and ‡ <0.05 and †† and ‡‡ <0.01. 
Figure 3-1B and 3-1D show the effect imaging region can have on water line width. 
Line widths approximately three times higher were observed for the Basal Ganglia 
imaging slice compared to a higher placed slice above the corpus callosum. A mean 
water line width of 0.07, 0.07 and 0.06ppm were observed across both regions for 
TE=35, 80 and 144ms respectively for voxels analyzed with the water line width criteria 
<0.1ppm. Poorer line widths were particularly observed in the frontal region of the basal 
ganglia slice through the brain. Magnetic field inhomogeneity effects, which result in 
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spectral line broadening, are most commonly observed in MRSI data where there is a 
close proximity to air-tissue interfaces e.g. the sinuses (79).  Poor line width increased 
fitting error resulting in a reduction in overall reproducibility. Short echo (TE=35ms) 
spectra had the greatest voxel loss of 38% of the total voxels across all scans and 
volunteers’ due to poor line width >0.01ppm; compared to 14% and 3% for TE=80ms 
and 144ms respectively. Analysis showed these voxels were localised predominantly 
in the basal ganglia region.         
3.3.5 The Effect of Echo Time and Macromolecular Analysis Schemes on 
Metabolite Quantitation 
Average white matter metabolite concentrations were calculated to assess the ability 
of the techniques to reproduce the expected metabolite concentrations and validate 
the overall quantitation methodology. The absolute metabolite concentrations taken 
from white matter voxels for each echo time and a comparison between Si.BL and 
Ex.Bl MM analysis schemes are shown in Table 3-6. Absolute concentrations for 
TE=35ms and 80ms were found to be consistent with those in the literature for healthy 
parietal white matter (70,80). For a TE=144ms a slight underestimation was observed 
suggesting accuracy maybe reduced at longer TE due to increased T2 relaxation. 
Additionally, it is also worth noting that differences in metabolite concentrations could 
be attributed to natural variation across volunteers. A percentage difference of below 
23% was found between Si.BL and Ex.BL across all echo times for tNAA, tCr and tCho. 
Larger differences especially for an echo time of 35ms were observed for poorly 
determined metabolites such as Gln, Glth and Tau. 
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Table 3-6 Average healthy volunteer metabolite concentrations for left and right white matter for TE=35, 80 and 144ms 
for both Ex.BL and Si.BL MM analysis schemes. A percentage difference Δ between Si.BL and Ex.BL is also shown. 
  TE=35ms TE=80ms TE=144ms 
Metabolite 
Mean 
Concentration 
(mmol) Δ (%) 
Mean 
Concentration 
(mmol) 
Δ 
(%) 
Mean 
Concentration 
(mmol) Δ (%) 
Si.BL Ex.BL Si.BL Ex.BL Si.BL Ex.BL 
tNAA 7.0 6.5 7.2 7.6 7.8 -1.3 5.7 6.6 -14.7 
tCr 4.9 4.5 9.3 3.6 3.5 1.4 2.3 2.3 -0.1 
tCho 1.4 1.3 9.1 1.1 1.1 1.6 1.0 1.0 3.6 
Glu 5.2 5.3 -2.9 4.0 4.0 0.0 1.0 0.9 17.2 
Gln 0.8 0.5 45.3 0.5 0.5 10.2 1.2 1.0 17.5 
Glx 6.0 5.8 3.9 4.5 4.5 1.2 2.2 1.8 17.4 
Ins 2.8 2.9 -3.5 3.6 3.5 1.8 1.3 1.3 -0.3 
Glth 1.0 0.3 66.1 0.7 0.8 -1.1 0.2 0.2 -34.5 
Tau 0.1 0.5 -543.6 0.4 0.4 -1.8 0.4 0.4 -2.9 
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3.4 Discussion 
The effect of echo time and macromolecular analysis schemes on 1H MRSI 
reproducibility has been investigated for three different echo times 35, 80 and 144ms 
and a comparison made between two different MM analysis schemes Si.Bl and Ex.Bl. 
An Ex.BL model was developed and optimised to extract a metabolite nulled MM signal 
for inclusion in the Ex.BL basis set. Overall, it was found that a TE=80ms was 
significantly more reproducible for the following five metabolites: tNAA, tCr, Gln, Glth 
and Tau. However, the short echo acquisition TE=35ms combined with Ex.BL 
performed significantly better for Glu and Glx. 
The experimentally acquired healthy volunteer baseline signal was found to be 
consistent between volunteers with respect to MM content.  This is found to further 
compliment the study by Snoussi et al (68), that suggested the use of a single MM 
baseline spectra could be sufficient to include in a basis set for the fitting of spectra. 
Residual metabolite peaks present in the metabolite nulled spectra due to their differing 
T1 relaxation properties, can be easily removed in post processing. Therefore, the 
resultant MM signal could be successfully introduced into the Ex.BL basis set.  
Metabolites tNAA, tCr and tCho within healthy brain spectra, are known to have higher 
SNR in comparison with other lower level metabolites. Therefore, as expected they 
were found to be the most reproducible. This can be attributed to an inherent increase 
in fitting precision compared to lower level metabolite signals. The use of an Ex.BL 
significantly improved the reproducibility compared to Si.BL for short TE spectra for 
four metabolites: tNAA, Glu, Glx and Tau. The Ex.BL model also found increased 
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performance for spectra with poor line widths – this method could therefore be used to 
improve the reliability of poor quality spectra. 
Several reproducibility studies exist within the literature. However, they are varied and 
cover a wide range of techniques, echo times and field strength. This means direct 
comparisons between studies can prove difficult. A recent study by Veenith et al (81), 
which used a simulated baseline model at TE=70ms, found within session 
reproducibility COVs of 9.9% for tNAA, 10.6% tCr and 14.3% for tCho compared to our 
studies values at TE=80ms of 6.03%, 7.18% and 8.16% for tNAA, tCr and tCho 
respectively using the Si.BL MM analysis scheme. Further improvement in our study 
at TE=80ms was observed with the use of an Ex.BL for the above metabolites with 
COVs of 5.35% for tNAA and 8.1% for tCho. Use of different methodologies between 
these two studies could attribute to the observed differences in results, some of which 
include: Spin-Echo versus PRESS acquisition, differing analysis software and a slightly 
different line width quality control criterion of <12Hz. Our protocol also had a slightly 
increased echo time of 80ms, which would allow MM signals to decay further, 
decreasing their contribution and potentially reducing their impact on the overall 
reproducibility. A combination of all these factors could have contributed to the 
improved reproducibility observed within our study.  
For some studies, protocols have been developed and tested for the optimized 
measurement of specific metabolites. A short echo time (TE=40ms) study by 
Gasparovic et al (82) at 3Tesla found comparable COV’s to our study of 5% for tNAA, 
6% Cr, 7% Cho, 11% Ins, 10% Glu and 13% for Glx. Their TE=40ms was chosen for 
optimized detection of Glu.   Additionally, a study by Jang et al (83) at a lower field 
strength of 1.5Tesla also found an optimal short TE of 40ms using PRESS for the 
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measurement of Glutamate. Comparable COV’s of 11 and 13.1% for anterior cingulate 
cortex and insula respectively were also found. In our study at TE=35ms a slightly 
increased COV of 16.33% was for Glu may have been found as our sequence had not 
been specifically optimized for this metabolite.  
There is a growing clinical interest in the use of MRS in the measurement of glutamate 
for the study of schizophrenia (84); brain tumor metabolism (85) and cognition (86). In 
this study, the combination of Ex.BL and an echo time of 35ms yielded the most 
reproducible measure of glutamate (COV=14%). This finding is in agreement with a 
previous study by Hancu et al, where simulations and in-vivo data were used to 
demonstrate that shorter TE acquisitions showed better reproducibility for glutamate 
measurements (87). Additionally, work by Mullins et al also found a shorter echo time 
to be optimal for Glu with CoV’s of 2.6% for TE=40ms and 7.6% for TE=80ms (88). 
Contrary to this, a study by Schubert et al (89), assessed the determination of 
glutamate using SVS at 3Tesla, proposed an intermediate TE of 80ms to be optimal. 
However, Schubert et al only focused on TE’s between 50ms and 330ms and did not 
evaluate short-echo spectra <50ms. In addition, macromolecular signals were not 
included in the analysis basis set, therefore analysis of echo times shorter than 50ms 
would have resulted in greater interference from macromolecular signals. In this study, 
for TE=80ms a COV of 17% for glutamate was achieved compared with 10% from 
Schubert et al, this difference may be attributed to the generally higher data quality 
available from SVS.  Whilst this study was focused on MRSI, it is worth noting that the 
findings here broadly agree with similar SVS studies measuring glutamate, this 
indicates our results may also be applicable to the design of SVS studies. Hancu and 
Port et al (90) suggest a TE=80ms is optimal for Glutamine with in vivo COVs of 12.7% 
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compared to 122% for a TE=35ms.  Due to dephasing, a shorter TE was better for 
Glutamate with simulation COV’s of 4.2% for TE=35ms and 5.1% for TE=80ms. This 
finding is in agreement with our study. Our study however shows increased variation 
for Glutamate as expected in vivo when compared to simulation. J-modulation effects 
for Glutamate at longer TE could explain why glutamate is dephased at longer TE, 
whereas glutamine can still be reliably measured. It is also worth noting that as 
glutamine is present in low levels in healthy subjects its reproducibility can be difficult 
to determine accurately.  
Another metabolite of interest within MRS studies is Lactate. Increased levels of lactate 
are thought to be associated with hypoxia or ischemia. Therefore this signal is widely 
measured in clinical MRS studies in order to investigate pathologies such as brain 
tumors and mitochondrial disease (10). A characteristic signal inversion at TE=144ms 
means this long echo time is often used for the measurement of lactate, due to an 
improved separation from lipid signals at 1.3ppm (10,91). As low levels of lactate exist 
in normal brain, this metabolite was not considered in this study, however this example 
highlights that a single echo time may not be optimal for all metabolites. Therefore, 
protocol optimization is important and will always benefit from prior knowledge of the 
important metabolites for a particular clinical question. However, in the absence of a 
prior hypothesis, a shorter TE with appropriate macromolecular and lipid analysis will 
give good results for most metabolites due to reduced multiplet dephasing and T2 
weighting. 
It is worth noting that in addition to metabolites, the MM spectral content itself is also 
of clinical interest, since it has been shown to provide additional information for a 
number of diseases, such as brain tumors where MM content was found to be useful 
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in assigning tumor grade (52). A recent mouse model study by Craveiro et al has 
shown that human glioma has exhibited several alterations in the macromolecule 
spectrum when compared to healthy controls corresponding to mobile lipids and also 
a broad MM component between 3.6 and 3.7ppm. This introduced significant errors 
into the quantification of Lac and Asp (92). Therefore, any difference in MM content 
due to pathology may need to be accounted for in order to maintain accurate metabolite 
quantification. This also suggests that a MM fitting model based on normal tissue may 
not be suitable for the analysis of some pathology.   Elevated levels of MM have also 
been observed in studies of multiple sclerosis (93) and stroke (56,63). The acquisition 
of MM spectra using an inversion recovery sequence for each patient would prove time 
consuming and may preclude its use in routine clinic. Therefore, as the MM content for 
pathological tissue is likely to differ from normative profiles in some diseases, the more 
flexible Si.BL analysis method should be chosen in the absence of a patient or disease 
specific MM profile. 
Whilst both echo time and macromolecular analysis schemes can influence the 
reproducibility of 1H MRSI spectra; data quality parameters such as water line width 
and SNR also have a significant impact. Echo time is inherently linked with SNR, and 
therefore is an important factor to consider for protocol optimization. Loss of signal 
limits the amount of metabolite information that can be observed at increased echo 
times, as lower level signals get closer to and become indistinguishable from 
background levels decreasing fitting accuracy. Water line width is another issue that 
can influence the reproducibility of spectra. Table 3-5 illustrates that if a rejection 
criterion is not set, the available reproducibility for each metabolite can increase 
drastically. For example, a twofold change in reproducibility can be observed in the 
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case of tNAA compared to water line width <0.1 ppm. Water line width is also 
dependent on imaging location, meaning voxel placement may become an issue in 
protocol design. In this study, poorer water line widths were observed for spectra 
collected with a slice going through the Basal Ganglia, particularly in the frontal region, 
due a closer proximity to susceptibility inducing air-tissue boundaries e.g. sinuses. This 
proved particularly problematic for short-echo spectra, resulting in the rejection of over 
a third of voxels due to water line width (>0.1ppm). This loss of information would prove 
particularly disadvantageous if the voxels discarded are in an area of pathological 
interest. 
This study demonstrates several factors are needed to be taken into consideration in 
MRSI protocol optimization including: echo time, macromolecular analysis schemes, 
metabolite of interest, location and data quality, all which are not necessarily 
independent from each other.  This study mainly focuses on the intra-subject 
reproducibility within the same session rather than accuracy. Metabolite concentrations 
were calculated for each echo time and MM analysis scheme and were found to be 
consistent with those previously published in literature for parietal white matter (70,80). 
A slight underestimation was found for a TE=144ms suggesting accuracy is decreased 
at longer TE which could be due to T2 bias on the metabolite estimates. True measures 
of accuracy are difficult to establish in volunteers and patients due to a lack of 
alternative methods for measuring NMR visible metabolite concentrations. For this 
reason, partial volume corrections for white matter, grey matter and cerebrospinal fluid 
were not required for this study - as COV measured were only performed between 
voxels with identical tissue constituents. Further work is needed to develop methods 
for establishing combined reproducibility and accuracy. 
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3.5 Conclusion 
In this study, echo time, macromolecular baseline analysis and data quality parameters 
were all found to impact the reproducibility of 1H MRSI data. These results highlight 
the importance of careful selection of echo time and analysis methodology where 
optimal reproducibility is sought for a primary metabolite of interest. Overall, this study 
found that a TE=80ms produced the most reproducible metabolite values for tNAA, 
tCho, tCr and Glth in healthy volunteers. However, the combined use of a short TE 
sequence and the MM analysis scheme Ex.BL may be preferred as a compromise 
between good accuracy, good SNR and T2 bias on metabolite estimates.  
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4. Sensitivity Encoding for fast 1H MRSI Water Reference Acquisition 
4.1 Introduction 
Absolute quantification of metabolite concentrations is important. However, the 
requirement for an internal standard water reference acquisition poses a challenge, as 
it increases acquisition time considerably for MRSI acquisitions. This can preclude its 
use in routine clinic. Absolute quantification has significant advantages over more 
commonly used ratios; firstly, ratios can become unstable particularly if the 
denominator metabolite is present in low concentrations. Secondly as all metabolites 
may be equally affected due to an overall increase or decrease in denominator, the 
determination of the cause/impact of a change can prove difficult. 
Fast-MRSI methods have been developed which reduce the scan time required to 
acquire both the metabolite and water reference data. As discussed previously in 
chapter 2, sensitivity encoding (SENSE) and reduced resolution (current Philips default 
MRSI protocol) are two techniques that can be used to speed up scan time; by either 
reducing the number of phase encoding steps or sampling fewer points in k-space 
respectively. The reduced resolution technique may primarily be used to assist in post 
processing steps; for example, phase correction and line shape correction but for this 
study we have focused on its use for absolute metabolite quantitation.  
An alternative to acquiring a water reference scan is to determine the absolute 
concentrations using an external reference system; Bonekamp et al (14) investigated 
the use of SENSE in conjunction with an external reference “phantom replacement” 
technique. This method is advantageous as no additional patient scan time is required. 
It also doesn’t rely on water content and relaxation time estimations as it uses a 
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standard with known concentration. It does however suffer from B1 inhomogeneity 
effects, further enhanced by the need for a larger Field of View (FOV), which also 
results in an increase in scan time.  
For SENSE spatial resolution is theoretically preserved, however increasing SNR loss 
is associated with higher reduction factors (94). As water reference data inherently has 
high SNR, we hypothesis that SENSE will be the superior in the collection of fast water 
reference data collection in comparison to the reduced resolution method.  
Therefore, as the SNR is extremely high for water reference data, we propose that in 
order to maintain accurate measurements of lower concentration metabolites, SENSE 
R=1 (no-under sampling) should be used for the collection of metabolite data and 
SENSE R=3 for water reference data collection. In this study, we compare the 
accuracy of the two fast methods – SENSE with reduction factor 3 in both directions 
and reduced resolution in their ability to reconstruct an equivalent fully sampled MRSI 
water reference acquisition. In order to do this a comparison between water amplitudes 
was made. The fast method which provided water amplitudes closest to the fully 
sampled method was regarded as most accurate. In order to validate the proposed 
methodology data was collected from three volunteers and a standard MRS (“braino”) 
phantom. This study has also been peer reviewed and published in Magnetic 
Resonance in Medicine journal (95). 
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4.2 Methods 
4.2.1 MRSI Data Collection 
All MR scanning was performed on a 3T Philips Achieva TX MR System using a 32-
channel head coil at Birmingham Children’s Hospital, UK. This study had full ethical 
approval and informed consent was obtained for all subjects.  
Data was collected from three healthy volunteers (aged between 20 and 25) and a 
“braino” MRS phantom containing the following constituents:10mM creatine hydrate, 
2mM choline chloride, 5mM dl-lactic acid, 1mL/L Gd-DPTA (Magnevist), 12.5mM 1-
glutamic acid, 7.5mM myo-inositol, 12.5mM N-acetyl-1aspartic acid (NAA), 0.1% 
sodium azide, 56mM sodium hydroxide (NaOH) and 50mM potassium phosphate 
monobasic (KH2PO4) (96).  
For MRSI grid positioning, an initial T1 weighted 3D Fast Low Angle Shot (FLASH) 
MRI 1mm isotropic reference scan was obtained. All MRSI grids were manually 
positioned above the corpus callosum (Figure 4-2a) with the following acquisition 
parameters: Field of View (FOV) matrix size 15x13; voxel size 13mm x 13mm x 13mm; 
TE=35ms; TR=2s; half echo acquisition mode. In each case PRESS localisation was 
applied to excite a 6x6 voxel region (78mm x 78mm x 13mm) centrally within the FOV. 
This corresponds to a fully excited 5x5 region with a ½ voxel margin outside the 
PRESS excitation region. Since NMR visible water concentrations are fairly constant 
throughout the head (~40M), we intentionally included these partially excited voxels 
(equating to a 7x7 region) in the analysis in order to ensure the fast MRSI methods 
could be used to accurately reconstruct non-uniform water distributions. In all MRSI 
examinations, in order to reduce acquisition time, the points of k-space outside the 
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elliptical boundary were not sampled (97). In post processing, a k-space hamming filter 
was applied to reduce ringing artefacts. No additional averaging was performed during 
k-space acquisition. 
Preliminary studies (Section 4.3.1) comparing the SENSE method with the fully 
sampled MRSI acquisition highlighted a systematic difference in scaling between 
SENSE and no SENSE acquisitions. This was due to a rescaling step required in the 
SENSE reconstruction. Therefore, to allow a true comparison between the SENSE 
R=3 and reduced resolution method, SENSE reconstruction was also enabled for both 
the reduced resolution and full acquisition scans with speed up factor R=1 (no under 
sampling) in both directions. Resultant scans therefore have a consistent scaling factor 
between the full acquisition, reduced resolution and SENSE methods. For the 
remainder of this study the following terminology will be used to describe each type of 
MRSI acquisition used: “full acquisition no-SENSE” will refer to the fully sampled MRSI 
grid no SENSE scaling, 153 phase encoding steps, scan time= 5 minutes 6 s; “full 
acquisition” will refer to the fully sampled MRSI grid with SENSE R=1 scaling, 153 
phase encoding steps, scan time= 5 minutes 6s; “reduced resolution acquisition” will 
refer to a 2x reduction in k-space sampling for both dimensions with SENSE scaling 
(R=1), 32 phase encoding steps, scan time= 1minute 4 s; and “SENSE acquisition” will 
refer to the standard SENSE reconstruction with a x3 reduction k-space sampling 
(R=3) for both dimensions, 28 phase encoding steps, scan time= 56s.    
Patient and phantom MRSI scans were performed in succession with identical FOV 
and PRESS geometries within each session. Each of the following scans were 
collected for both patient and phantom data: full acquisition no-SENSE; full acquisition 
(R=1); SENSE R=3 acquisition; and reduced resolution acquisition. 
 71 | P a g e  
 
 
4.2.2 Data Analysis 
All MRSI spectra were exported into DICOM format from the scanner work station and 
imported into TARQUIN MRS quantitation software (24) for analysis. Water amplitude 
measurements were made in time domain by back extrapolating the initial part of the 
FID to time=0 (methodology provided in (24)). The calculated water amplitudes for 
each voxel within the FOV were imported into MATLAB R2012a software for statistical 
analysis. Water amplitude maps of the grid were generated for each acquisition; full 
acquisition no-SENSE, full acquisition (R=1); SENSE R=3 acquisition; and reduced 
resolution acquisition. Subsequent analysis was performed on all voxels within the 
PRESS excitation (Volume of Interest (VOI)) and the partially excited region (7x7 grid). 
Bland Altman plots and associated statistics (64) as detailed in chapter 2 were used to 
measure the agreement between the different MRSI acquisition protocols, in order to 
establish the most accurate fast-MRSI technique. 
This studies analysis also focused on the average across voxels in order to ease the 
ability to make direct comparisons between subjects and literature values. Although an 
advantage of MRSI is the increase in spatial specificity for individual cases, when 
comparing multiple subjects’ due to the large amount of data acquired an average 
comparison is more suitable. 
4.3 Results 
4.3.1 Scaling of sensitivity encoded MRSI data in comparison with the full 
acquisition (no-SENSE). 
In order to validate the use of full acquisition (R=1) as a valid comparator data set for 
the fast-MRSI techniques, quantitative analysis was performed between the full 
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acquisition and full acquisition (no-SENSE) data. Figure 1 shows a Bland Altman plot 
between the full acquisition methods for a phantom and volunteer data set. The mean 
difference and standard deviations in amplitude between the no-SENSE and SENSE 
R=1 full acquisitions were -0.13 ± 3.62% for a phantom and was slightly increased for 
volunteers with a mean difference of -0.48 ± 5.51% (Figure 4-1). 
 
Figure 4-1 Water amplitude Bland-Altman plots to assess variance between full 
acquisition (SENSE R=1) and full acquisition no-SENSE for a) phantom and b) 
volunteer data. 
 
4.3.2 Comparison between full acquisition and fast-MRSI techniques 
Water amplitude maps (Figure 4-2b) were produced for the 6x6 PRESS excitation VOI 
(Figure 4-2a) for the full acquisition and fast-MRSI methods for both volunteer (shown 
in Figure 4-2b) and phantom data. An initial visual inspection of the water amplitude 
intensity maps (Figure 4-2b) clearly shows that SENSE R=3 has proven to be superior 
in producing a more accurate reconstruction of the full acquisition data when compared 
to the reduced resolution method.  
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Figure 4-2 (a) MRSI geometry for volunteer 2 including 6x6 voxel PRESS 
volume which is collocated with the shim box shown in orange; (b) water 
amplitude maps extracted from volunteer 2 for full acquisition; reduced 
resolution acquisition; and SENSE acquisition (R=3) 
 
The mean differences and standard deviations between full acquisition compared to 
SENSE and versus the reduced resolution acquisitions are shown in Table 4-1 for both 
the phantom and volunteers. These were calculated in order to determine any 
systematic or random distributed differences between the full acquisition and the fast-
MRSI techniques. For SENSE acquisition within the “braino” phantom a mean 
difference in water amplitude of 2.31 ± 2.09% with low variability observed about the 
mean. Increased variability in the phantom study was observed with the reduced 
resolution technique with mean difference and standard deviation of 11.1 ± 11.1%.  
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Table 4-1 Comparison of mean differences between reduced resolution x2 and 
SENSE R=3 Vs full acquisition MRSI. 
Water Amplitude/ Max amplitude (%) 
  Mean 
difference 
Standard 
Deviation 
SENSE 
R=3 Vs 
Full 
Acquisition 
Braino Phantom 2.31 2.09 
Volunteer 1 0.75 2.95 
Volunteer 2 2.49 3.40 
Volunteer 3 3.17 3.21 
 
Reduced 
Resolution 
x2 Vs Full 
Acquisition 
Braino Phantom 11.11 11.09 
Volunteer 1 9.87 10.16 
Volunteer 2 11.19 11.12 
Volunteer 3 9.95 10.96 
 
Results between volunteers were generally consistent with similar errors found 
between the phantom and volunteer studies for both fast-MRSI methods. The average 
mean and standard deviation was 2.1 ± 3.2% and 10.3 ± 10.7% for the SENSE 
acquisition and reduced resolution techniques respectively. The use of SENSE 
provided approximately three times more accuracy than the reduced resolution 
method, both in terms of systematic bias and randomly distributed differences. These 
statistics are also consistent with the visual differences observed in the intensity maps 
shown in Figure 4-2b.  
4.3.3 Water amplitude MRSI reproducibility 
Duplicate full acquisition (R=1) and SENSE (R=3) water reference scans were 
acquired for both volunteer and phantom data sets in order to assess the reproducibility 
 75 | P a g e  
 
 
of these techniques. The mean water amplitude difference and its standard deviation 
was determined between repeats. A mean difference of -0.02 ± 0.26% and -0.45 ± 
0.8% for the full acquisition (R=1) phantom and volunteer scans was observed 
respectively. An increase in SENSE factor to R=3 resulted in a mean amplitude 
difference between repeated scans for the phantom of 0.26 ± 0.34% and   -0.94 ± 1.1% 
for the volunteer. Better reproducibility was observed within the phantom for both 
cases, suggesting that subject motion introduces an additional random error of less 
than 1%.  
4.3.4 Phantom metabolite concentration using SENSE and reduced resolution 
water reference data 
The water reference data from SENSE (R=3) and the reduced resolution technique 
were used to estimate the absolute metabolite concentrations found within the “braino” 
phantom. The same fully sampled (R=1) water suppressed data was used for both 
analyses to ensure any differences could be attributed to the water reference data. The 
following metabolites with known concentrations were present within the phantom: 
12.5mM total N-acetyl-laspartic acid (tNAA), 10mM Creatine (tCr), 2mM total Choline 
(tCho) and 12.5mM Glutamate (Glu). Mean metabolite concentrations were extracted 
from the central fully excited 5x5 voxel region. Metabolite estimations were found to be 
more accurate with the use of SENSE R=3 compared to the reduced resolution 
technique in the collection of water data (Table 4-2).  
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Table 4-2 Braino phantom absolute mean concentration across the VOI for 
SENSE R=1 metabolite data calibrated with SENSE R=3 and reduced resolution 
water reference data 
 SENSE R=3 Reduced Resolution 
 
 
Metabolite 
Mean 
Concentration 
(mM) 
Standard 
Deviation 
(mM) 
Mean 
Concentration 
(mM) 
Standard 
Deviation 
(mM) 
tNAA 11.98 1.14 16.01 2.71 
tCr 9.75 1.49 12.92 2.29 
tCho 2.72 0.47 3.61 0.72 
Glu 13.70 1.07 18.39 3.43 
 
A consistent over estimation in metabolite concentrations was found for the reduced 
resolution technique due to an incorrect increased water amplitude estimation at the 
PRESS box edges (Figure 4-3). It can also be seen that SENSE provides a more 
uniform metabolite distribution as would be expected within a phantom.  
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Figure 4-3 NAA concentration map from a) reduced resolution water reference 
data and b) SENSE (R=3) water reference data for the central 5x5 region. 
4.3.5 Parietal white matter metabolite concentrations using SENSE and 
reduced resolution water reference data 
Volunteer absolute concentrations were extracted using the TARQUIN algorithm in 
order to demonstrate the feasibility of combining fully sampled water suppressed data 
with fast-MRSI water reference data. Left and right parietal white matter voxels (six in 
total) were taken for each of the three volunteers. Table 4-3 shows the average 
volunteer metabolite concentrations using SENSE (R=3) and reduced resolution water 
reference data across the six voxels for tNAA, tCr, tCho and Glu. 
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Table 4-3 Average metabolite concentrations, using SENSE R=3 and reduced 
resolution water data, across three volunteers, the mean is taken from 6 
parietal white matter voxels (two from each volunteer). 
 Parietal White matter 
SENSE R=3 
Parietal White Matter 
Reduced Resolution 
 
 
Metabolite 
Mean 
Concentration 
(mM) 
Standard 
deviation 
(mM) 
Mean 
Concentration 
(mM) 
Standard 
deviation 
(mM) 
tNAA 8.53 0.30 10.62 0.34 
tCr 5.56 0.16 6.89 0.15 
tCho 1.14 0.14 1.41 0.19 
Glu 5.45 0.21 6.77 0.18 
 
Metabolite concentrations determined using SENSE (R=3) water reference data were 
found to be more consistent with those found within the literature for healthy volunteers 
(70,80) whereas the reduced resolution technique also overestimated these values.  
4.4 Discussion 
The purpose of this study was to validate the use of SENSE for the collection of fast-
MRSI water reference data within the brain for the absolute quantification of 
metabolites. A comparison was made between SENSE and reduced resolution 
acquisitions in their ability to (i) reconstruct fully sampled volunteer and phantom data; 
(ii) reproduce known metabolite concentrations from phantom data, and (iii) produce 
metabolite concentrations from healthy volunteers. SENSE proved superior and 
offered significant improvement in accuracy over the reduced resolution method. To 
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the best of the author’s knowledge this is the first study to have validated the use of 
SENSE for the purpose of water reference data collection. 
Improvement in accuracy with the use of SENSE particularly at the edges of the 
PRESS excitation region (Figure 4-2) was expected; as the reduced resolution 
technique involves zero-filling in k-space, effectively applying an interpolation. SENSE 
instead is based on k-space reconstruction rather than an interpolation. For the 
reduced resolution method, with a given spatial dimension, the point spread function 
is inversely proportional to the number of acquired phase encoding points (for a fixed 
FOV) – rather than the number of zero-filled points. Therefore, SENSE can provide 
improved resolution over a time-equivalent reduced resolution acquisition. 
Whilst this study has not directly tested the accuracy of the methods on water 
concentration distributions in highly heterogeneous tissue, the heterogeneity caused 
by the PRESS excitation boundary (1/2 voxel margin) is a valid model for testing 
accuracy. We therefore expect that a similar investigation into heterogeneous tissue 
water distributions, for example in pathology, would yield comparable results. 
Furthermore, accurate measures of water amplitudes for use in metabolite quantitation 
close to the boundary of the PRESS excitation region are desirable, and it is clear from 
this study that SENSE outperforms the reduced resolution method in these regions. 
Absolute metabolite quantitation is generally desired over metabolite ratios, because 
in the case of ratios, the source of variation for a given ratio cannot be determined as 
to whether it is due to a relative increase in one metabolite or a decrease in the other 
(31). Whilst the collection of fast accurate water reference data for metabolite 
quantitation in MRSI was the primary objective for this study; the collection of water 
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reference data could also prove useful for the measurement of the “proton resonance 
frequency shift” for use of non-invasive thermometry (98). Therefore, this type of 
acquisition could be used in the generation of temperature maps across the brain.  
An alternative approach to absolute quantitation is to perform pattern recognition 
directly on the acquired spectral data. These methods can prove advantageous as they 
are relatively straightforward to implement as the required statistical methodology e.g. 
independent component analysis are readily available. There is also no additional scan 
time required which can prove appealing due to clinical scan time constraints. 
However, as seen in the previous chapter MRS data can have issues which these 
methods are not optimised to deal with, e.g. variable line widths, unstable baselines 
and residual water. Therefore, the best approach would be to apply pattern recognition 
to the absolute quantitative data, this has been previously demonstrated in both 
paediatric and adult brain tumour studies (99,100). 
MR protocol development presents a compromise between scan-time, spatial 
resolution (voxel size) and the effect of unwanted T1 and T2 weighting. The protocol 
we have presented in this study addresses the issue of scan time and provides the 
option of absolute concentrations for a minimal increase (<1 min) in scan time. MRSI 
resolution is comparatively poor compared to other MR techniques. However, the 
additional spectral dimension allows a non-invasive insight into tissue metabolism. 
Meaning MRSI is ideal for the investigation of certain pathologies such as cancer. The 
MRSI parameters used for this study were chosen to represent typical values for 
clinical MRSI acquisitions where short scan times are particularly important. Despite 
partial volume effects and incomplete relaxation, useful clinical information can be 
obtained from the voxel sizes and repetition times used within this study.  
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Data quality is an important factor to consider. The use of sensitivity encoding produces 
an inherent reduction in SNR. The quality of metabolite information acquired using 
SENSE has previously been assessed by several groups concluding no significant 
losses were found in comparison with full acquisition data (14,101,102). A study by 
Bonekamp et al (14) used a sense factor R=2 and observed excellent spectral quality. 
Excellent agreement was found for the ability of SENSE to reconstruct the full 
acquisition (no under sampling) data.  However, high SNR losses were found by Van 
Cauter et al for low concentration metabolites such as myo-inositol for a SENSE factor 
of R=3.6 (73). To preserve these lower concentration metabolites, we propose the use 
of SENSE R=1 for the collection of metabolite data and SENSE R=3 for water 
reference data collection. This allows a reduction in scan time for both metabolite and 
water reference data from 10 min 16s to 6min 6s.  
 Two other methods that have proven promising for the acceleration of MRSI data 
collection are (1) EPI methods such as PEPSI (16,17) and (2) compressed sensing 
(103). In this study, we decided to focus on SENSE due to its wider commercial 
availability and therefore greater clinical relevance. The strategy of sacrificing SNR 
rather than resolution is an effective one for the collection of water reference data as, 
unlike metabolite data, you can afford a decrease in SNR as the water signal is 
extremely high. We propose that other fast-MRSI methods that follow this example will 
be similarly successful. Particularly the use of compressed sensing, in isolation or in 
combination with SENSE may offer a further reduction in scan time and therefore would 
make an interesting extension to this work. 
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4.5 Conclusion 
SENSE has been shown to be approximately three more times more accurate than the 
“gold standard” reduced resolution technique for acquiring fast MRSI water reference 
maps. When compared to the fully sampled acquisition water amplitude differences 
were found to be less than 4% with the use of SENSE. Healthy volunteer parietal white 
matter concentrations were found to be comparable with literature when using the 
SENSE method. Whereas, the reduced resolution technique overestimated these 
values. These findings validate the use of SENSE MRSI for the accurate collection of 
water reference data in a feasible time frame for the purposes of absolute metabolite 
quantitation in a clinical setting.  
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5. Sensitivity Encoding for fast 1H MRSI Water Reference Acquisition: A Clinical 
Implementation 
5.1 Introduction 
In Chapter 4, the use of sensitivity encoding (SENSE) for fast 1H MRSI water reference 
acquisition was validated. White matter metabolite concentrations were extracted for 
healthy volunteers by collecting a fast-water reference acquisition in conjunction with 
a fully sampled (SENSE R=1) water suppressed acquisitions. Values obtained were 
found to be comparable to those within the literature (95). In this chapter, the clinical 
implementation of this protocol is assessed with respect to data quality and its success 
in differentiating between patients with known diseases and healthy volunteers. 
MRSI data was acquired from two patient groups: Wolfram Syndrome and Brain 
Tumour Survivors. Wolfram syndrome is a rare condition which is an autosomal 
recessive genetic disease. It presents as a combination of insulin dependent diabetes 
mellitus, optic nerve atrophy, diabetes insipidus and deafness (104). It was initially 
believed that neurological deficit appears at the later stages of this disease (105). 
However, more recent studies have shown neurodegeneration is present at the early 
stages of the syndrome (106–108) although there are still studies that contradict this 
(109). Neurodegeneration in the posterior fossa and in particular the pons is 
increasingly well recognized but degeneration in the supratentorial region is less well 
established. 
Approximately two out of every three paediatric patients diagnosed with brain tumours 
will become long term survivors. Brain Tumour Survivors (BTS) commonly suffer late 
effects to their overall neurological function including neuro-cognition. This can be 
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attributed to: direct neurological damage to the developing brain due to; brain tumour 
removal, long-term chemotherapy toxicity effects and the effects of radiotherapy to the 
central nervous system (110). These are particularly prominent when tumours are 
diagnosed and treated at a young age but the deficits can evolve slowly over a long 
period of time. Conventional MRI appearances commonly correlate poorly with current 
and in particular future neurocognitive deficits. A number of studies have looked at the 
use of MRI in the study of Paediatric Brain Tumour Survivors (111–114) using a variety 
of structural and functional imaging techniques including fMRI, Diffusional Tensor 
Imaging (DTI) and SVS. Previous MR Spectroscopy studies (111,112) have looked at 
metabolite ratios to assess brain tissue damage and neuronal function recovery. 
Reduction in tNAA levels along with elevated tCho are indicative of neurodegeneration 
(5). The identification of metabolite biomarkers using MRSI in the study of long term 
brain tumour survivors (BTS) could provide more insight into post-treatment effects 
and neurodegeneration. 
This study aimed to assess the clinical implementation of the fast 2D MRSI protocol 
developed in Chapter 4 (95). Data quality, along with the ability to distinguish between 
“normals”, patients with Wolfram syndrome and Brain Tumour Survivors (BTS) was 
assessed to see if any metabolite biomarkers of neurological dysfunction could be 
identified. 
5.2 Methods 
All MR scanning was performed on a 3 Tesla Philips Achieva TX MR system with a 
32-channel head coil at Birmingham Children’s Hospital, UK. All patients and 
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volunteers who participated in the study gave their informed consent under full ethical 
approval. 
5.2.1 MRSI data collection 
Data was collected from 16 subjects: 8 Brain Tumor Survivors (BTS) whose primary 
brain tumour was located in the posterior fossa, 7 Wolfram patients and 3 healthy 
volunteers. One patient from both the BTS and Wolfram patient groups was excluded 
due to incorrect grid positioning resulting in a final study cohort of 7 BTS (Table 5-1), 
6 Wolfram patients (Table 5-2) and 3 healthy volunteers (Table 5-2). 
Table 5-1 Brain Tumour Survival Group Cases: Age, Tumour Type and 
Treatment Details 
Case Age Group Treatment 
1 14.1 BTS - Pilocytic Astrocytoma  Surgery 
2 10.3 BTS - Ependymoma Surgery + Chemotherapy + Focal RT to PF 
3 13.8 BTS - Ependymoma Surgery + Chemotherapy + Shunt (Right) 
4 10.3 BTS - Pilocytic Astrocytoma Surgery 
5 16.2 BTS- Pilocytic Astrocytoma Surgery 
6 11.5 BTS - Medulloblastoma Surgery + Chemotherapy + Cranio-spinal RT 23.4 Gy 
7 13.8 BTS - Pilocytic Astrocytoma Surgery + Chemotherapy 
 RT = Radiotherapy and PF= Posterior Fosser 
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Table 5-2 Wolfram and Healthy Volunteer Case Ages 
Case Age Group 
8 13.0 Wolfram 
9 18.5 Wolfram 
10 14.9 Wolfram 
11 14.8 Wolfram 
12 13.3 Wolfram 
13 9.4 Wolfram 
14 23.0 Healthy Volunteer 
15 23.2 Healthy Volunteer 
16 23.0 Healthy Volunteer 
 
For MRSI grid positioning, a 3D T1 axial MRI already acquired within the scanning 
session was selected in order to plan on the standard axial plane. For cases 1 to 13 
all MRSI grid positions were placed manually so that the bottom of the slice was just 
touching the inferior aspect of the corpus callosum (Figure 5-1a-c). Data collected from 
healthy volunteer cases (14 to 16) were taken from the study detailed in Chapter 4 with 
the MRSI grid manually placed above the corpus callosum. Water suppressed with 
sensitivity encoding (SENSE) Factor R=1 and unsuppressed with SENSE Factor R=3 
acquisitions were acquired separately with the following acquisition parameters: Field 
of View (FOV) matrix size 15x13; voxel size 13mm x 13mm x 13mm; TE=35ms; TR=2s; 
half echo acquisition mode. In each case PRESS localization was applied to excite a 
6x6 voxel region (78mm x 78mm x 13mm) centrally within the FOV. In order to remove 
the effect of outer volume excitation only voxels from the central 5x5 region were 
analyzed. In all MRSI acquisitions, in order to further reduce acquisition time, the points 
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of k-space outside the elliptical boundary were not sampled (97). In post processing, a 
k-space hamming filter was applied to reduce ringing artefacts. No additional averaging 
was performed during k-space acquisition.  
 
Figure 5-1 Example subject MRSI Grid Planning Screen Shot (A-C), Water Line 
Width (D), Signal to Noise Ratio (E) and NAA Concentration Map (F) 
5.2.2 Spectral Fitting 
All spectral analysis was performed using the TARQUIN software package (23). 
Spectra were fitted using the Experimental Baseline (Ex.BL) basis set optimized in 
Chapter 3. An average healthy volunteer macromolecule (MM) spectrum was compiled 
and narrow metabolite signals for NAA, NAAG, TCho, TCr and TCrCH2 included in the 
basis set.  
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5.2.3 Data analysis  
MRSI spectra exported from the scanner workstation in DICOM format were imported 
into TARQUIN. Subsequent data analysis was performed using Python programming 
language. Spectra were assessed with respect to data quality parameters Signal-to-
Noise Ratio (SNR max) and Water Line Width (FWHM). Spectra were subject to a 
Water Line Width rejection criterion >0.1ppm. The number of voxels excluded due to 
this was calculated for each subject to assess the robustness of this protocol in a 
clinical setting. Mean white matter metabolite concentrations were calculated for each 
patient group and compared to healthy volunteers and values within the literature. 
Mean parietal white matter concentrations were taken from four voxels for each patient 
case and healthy volunteer. Grey matter concentrations were not calculated as the 
central voxels contained multiple tissue types making its separation difficult. The ability 
of the technique to separate between patient groups and healthy volunteers using the 
calculated mean white metabolite concentration and metabolite ratios for each subject 
was also assessed using a one-way ANOVA test using Microsoft excel. The degrees 
of freedom within groups for this test across the three subject groups is 13 and 2 
between groups. Mean metabolite concentrations were calculated from 4 white matter 
voxels for each case. Two sample T-tests were then used to assess the significance 
of any separation between groups, the P Value as consistent with the literature has 
been used as a measure of statistical significance. This analysis focused on the 
average across voxels in order to ease the ability to make direct comparisons between 
subjects and “normal” values. Although an advantage of MRSI is the increase in spatial 
specificity for individual cases, when comparing multiple subjects due to the large 
amount of data acquired an average comparison is more suitable.  
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5.3 Results 
5.3.1 The Effect of Sensitivity Encoding on the Quality of Clinical Data 
Mean SNR, Water FWHM and respective standard deviations across the PRESS 
excitation Volume of Interest (VOI) was calculated for each case. Acceptable mean 
SNR across the VOI was found with a value >15 found across all patients. Lower SNR 
was observed for Case 3, 5 and 12. For Case 3 a right shunt has been placed which 
may explain the loss in the signal for this region. Higher variability across the VOI in 
SNR was also observed for these cases.  
Table 5-3 Mean SNR and Water FWHM and their respective standard deviations 
for each patient case VOI 
Group Case SNR max 
Standard 
Deviation 
Water FWHM 
(PPM) 
Standard 
Deviation 
BTS 
1 56.31 6.84 0.06 0.00 
2 48.10 3.80 0.05 0.01 
3 29.01 15.58 0.06 0.03 
4 38.10 4.37 0.06 0.01 
5 20.33 24.90 0.04 0.05 
6 40.47 1.43 0.06 0.00 
7 54.34 4.55 0.05 0.00 
Wolfram 
8 47.71 1.84 0.08 0.01 
9 34.50 17.31 0.06 0.03 
10 45.52 8.81 0.08 0.01 
11 41.27 20.74 0.06 0.03 
12 18.65 22.91 0.04 0.05 
13 65.41 3.64 0.06 0.01 
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Overall, acceptable water line width was found across all subjects. Increased variability 
in water line width across the VOI was also observed for the cases 3, 5 and 12. 
5.3.2 The Effect of Water Line Width on Voxel Loss 
The number of voxels lost due to a rejection criterion of 0.1ppm was calculated for 
each case (Table 5-4). For 8 out of 13 patient cases no voxels were excluded due to 
this criterion. The maximum percentage of voxels lost across all volunteers was 20%. 
Thus, the minimum number of voxels remaining was 20. This demonstrates the 
robustness of this protocol which would allow more metabolite information to be 
obtained accurately compared to a single voxel acquisition. Figure 5-2 shows an 
example of the voxel loss locations for Case 3. Close proximity to the right shunt could 
be the cause of poorer quality spectra within this region. Inhomogeneity effects due to 
ineffective shimming across this region, due to the shunt, may have resulted in the 
exclusion of voxels due to our rejection criterion. Increased line width can be observed 
for the remaining voxels located near this physiological feature. Voxel loss is also 
observed in the frontal region which could be attributed to closer proximity to air-tissue 
interfaces i.e. the sinuses resulting in broadened line widths. 
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Table 5-4 Subject voxel loss due to rejection line width criterion >0.1ppm 
Group Case Group Voxels lost Voxels lost % 
BTS 
1 BTS 0 0 
2 BTS 0 0 
3 BTS 4 16 
4 BTS 0 0 
5 BTS 4 16 
6 BTS 0 0 
7 BTS 0 0 
Wolfram 
8 Wolfram 0 0 
9 Wolfram 3 12 
10 Wolfram 0 0 
11 Wolfram 5 20 
12 Wolfram 5 20 
13 Wolfram 0 0 
  Total 21 6 
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Figure 5-2 Water Line Width Map for Case 3 showing voxels lost due to Water 
Line Width Rejection Criterion 
5.3.3 Mean White Matter Concentrations: A Comparison between Patient 
Groups and Healthy Volunteers 
Mean white matter metabolite concentrations for tNAA, tCr and tCho were obtained for 
each patient case by taking the average of 4 manually selected voxels within this region 
for each subject (Table 5-5). White matter concentrations were also obtained from 
three healthy volunteers to act as a comparator group (Table 5-6). Figure 5-3A and B 
show the mean tNAA and tCho concentration for each subject case. It is unclear from 
these plots as to whether there is separation between the groups. Therefore, an 
ANOVA test was performed to assess whether the white matter concentrations for 
tNAA and tCho were significantly different between these three groups. For tNAA they 
were found to be significantly different (P<0.05, F = 5.7 and F Critical=3.8). However, 
no significance was found for tCho (P=0.13, F= 2.4 and F Critical = 3.8). Subsequent 
t tests were performed between groups to see what this difference for tNAA was 
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attributed to. Brain tumour survivors were compared to the Wolfram patient group; no 
significant difference was found (P=0.08, degrees of freedom=11 and Cohens d=1.72). 
A t-test between Wolfram and the healthy volunteer group was found to be significantly 
different (P<0.05 P=0.03, degrees of freedom=4 and Cohens d=3.74), this is further 
illustrated in Figure 5-3C and 3D. However, the difference between the Healthy 
Volunteer group and Brain Tumour Survivor patients for tNAA was not found to be 
significant (P=0.11, degrees of freedom=8 and Cohens d= 1.88). However, when the 
Wolfram and Brain Tumour Survivor patients are grouped and a t-test performed 
against the “Normal” group a significant difference is found (P=0.01, degrees of 
freedom=14 and Cohens d=2.9). Overall, we conclude that our protocol has the ability 
to be successful in distinguishing between these two subject groups with the caveat 
that the number of healthy volunteers is very small.  
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Figure 5-3 (A) Mean tNAA Concentration for each subject (B) Mean tCho 
Concentration for each subject (C) Plot of tCr versus tNAA for each patient 
group to show separation (D) tCr versus tNAA plot to show separation between 
Wolfram and Healthy Volunteers 
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Table 5-5 Mean White Matter Metabolite Concentrations and their standard deviation for Brain Tumour Survivors 
(BTS) and Wolfram Patients 
Group NAA Concentration mM Cr Concentration mM Cho Concentration mM 
BTS Mean Std Mean Std Mean Std 
1 7.74 0.57 4.60 0.69 1.19 0.12 
2 7.32 0.70 4.75 1.69 1.41 0.40 
3 7.48 0.46 5.44 1.55 1.58 0.50 
4 7.99 0.18 4.43 0.80 1.57 0.20 
5 6.99 0.57 4.88 1.54 1.19 0.42 
6 7.05 0.72 5.38 1.95 1.67 0.55 
7 8.89 0.62 4.79 0.84 1.31 0.29 
Wolfram Mean Std Mean Std Mean Std 
8 7.40 0.63 5.18 1.56 2.23 0.45 
9 6.76 0.66 3.73 1.16 1.38 0.33 
10 6.95 0.72 4.73 1.54 1.68 0.43 
11 6.74 0.33 6.89 0.86 2.22 0.23 
12 7.81 1.04 4.55 1.58 1.56 0.43 
13 6.03 0.30 4.15 0.66 1.32 0.29 
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Table 5-6 Mean White Matter Metabolite Concentrations and their Standard Deviations for Healthy Volunteers 
Group NAA Concentration mM Cr Concentration mM Cho Concentration mM 
Healthy 
Volunteer 
Mean Std Mean Std Mean Std 
14 8.52 0.52 5.17 1.71 1.54 0.30 
15 9.07 0.41 5.35 1.31 1.41 0.47 
16 7.77 0.42 5.19 1.69 1.21 0.42 
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5.4.4 Metabolite Ratios: A Comparison between Patient Groups and Healthy 
Volunteers   
Metabolite ratios were also calculated in order to assess whether our protocol could 
distinguish between patient groups and healthy volunteers (“Normals”) using 
metabolite ratios. Mean metabolite ratios were calculated (Table 5-7) and plots for 
tNAA/tCr (Figure 5-4A), tNAA/tCho (Figure 5-4B) and tCho/tCr (Figure 5-5) were 
created. Clear separation cannot be observed from the plots alone. An ANOVA test 
was performed for each of these metabolite ratios. A significant difference between 
subject cases was found for tNAA/tCho (F = 6.7 and F Critical=3.8) and tCho/tCr (F = 
7.7 and F Critical=3.8) only with P<0.01. For tNAA/tCho a significant difference was 
observed between Brain Tumour Survivors and Wolfram patients (P<0.05, degrees of 
freedom=11 and Cohens d=1.69) and Wolfram and “Normal” Subjects (P<0.01 
degrees of freedom=7 and Cohens d=3.85). A significant difference was also observed 
for these groupings for tCho/tCr with a P<0.05 for both (degrees of freedom, Cohens 
d = 10, 44.27 and 7, 56.92 for BTS and Wolfram and Wolfram and “Normal” subjects 
respectively). For both the absolute concentrations and metabolite ratios a significant 
difference was observed between Wolfram and Normal subjects suggesting this 
patient group has a greater difference from “normal” metabolite values. The use of 
metabolite ratios also found a significant difference between the two patient groups: 
Wolfram and Brain Tumour Survivors. The complimentary use of metabolite ratios and 
absolute concentrations together could provide further assistance in the separation of 
“diseased” and “non-diseased” brain tissue.
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Table 5-7 Mean Metabolite Ratios NAA/Cr, NAA/Cho and Cho/Cr and their Standard Deviations for Brain Tumour 
Survivors (BTS), Wolfram Patients and Healthy Volunteers 
Group NAA/Cr NAA/Cho Cho/Cr 
BTS Mean Std Mean std Mean std 
1 1.68 0.28 6.51 0.82 0.26 0.05 
2 1.54 0.57 5.19 1.57 0.30 0.14 
3 1.37 0.40 4.74 1.53 0.29 0.12 
4 1.80 0.33 5.09 0.67 0.35 0.08 
5 1.43 0.47 5.89 2.14 0.24 0.12 
6 1.31 0.49 4.23 1.47 0.31 0.15 
7 1.86 0.35 6.78 1.56 0.27 0.08 
Wolfram Mean Std Mean Std Mean Std 
8 1.43 0.45 3.31 0.72 0.43 0.16 
9 1.81 0.59 4.89 1.27 0.37 0.15 
10 1.47 0.50 4.15 1.14 0.35 0.15 
11 0.98 0.13 3.04 0.34 0.32 0.05 
12 1.72 0.64 5.02 1.52 0.34 0.15 
13 1.45 0.24 4.56 1.02 0.32 0.09 
Healthy 
Volunteers Mean Std Mean Std Mean Std 
14 1.65 0.55 5.55 1.15 0.30 0.11 
15 1.70 0.42 6.43 2.17 0.26 0.11 
16 1.50 0.49 6.40 2.24 0.23 0.11 
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Figure 5-4 Mean metabolite ratios and their standard deviations for each 
subject case for (A) tNAA/tCr and (B) tNAA/tCho 
 
 
Figure 5-5 Mean metabolite ratios and their standard deviations for each 
subject case for tCho/tCr 
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5.4 Discussion 
The use of sensitivity encoding for fast-MRSI water reference data collection for the 
absolute quantitation of metabolite information has been implemented clinically. For 
thirteen of the initial fifteen patient subjects correctly positioned data was acquired. 
Resulting in a success rate of 86% for its clinical implementation. The two patients with 
incorrect positioning of the MRSI grid were excluded from further analysis. These 
instances were early on in the study and took place without an MR Physicist present. 
Further assistance and training was subsequently provided to the radiographer and 
accurate MRSI grid positioning was achieved.  
A robust protocol has been developed, with 62% of our cohort obtaining good quality 
data (Water Line Width <0.1ppm) for the whole PRESS excitation region. A maximum 
of 5 voxels out of 25 were excluded across the remaining subjects. Acceptable 
SNR>10 was also obtained across all subjects. Mean white matter concentrations were 
calculated and significant differences for tNAA were found between the Wolfram 
patient group and “normals”. The use of metabolite ratios tNAA/tCho and tCho/tCr in 
conjunction with absolute concentrations also allowed a distinction to be made 
between the Wolfram and “normal” data sets. These metabolite ratios were also able 
to distinguish between Brain Tumour Survivors and Wolfram patient groups proving 
metabolite ratios do have their merit within MRSI studies. 
For tNAA white matter concentrations the difference between Brain Tumour Survivors 
and healthy volunteers was not found to be significant. However, as tNAA is a marker 
of neuronal integrity it is an important metabolite in the detection of neurocognitive 
deficit. All BTS subjects within this study had no history of metastatic disease present 
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within this imaging region. The imaging of white matter regions however is of interest 
as indicators of neurocognitive defects present themselves here (115,116).  Reduced 
levels of this metabolite compared to normal would suggest an increase in brain 
neuronal damage. Patients undertaking this study as shown in Table 5-1 undertake a 
variety of treatment pathways which could affect their final prognosis. A limitation of 
this study is the cohort size for each treatment and tumour type. Data collection from 
more subjects could allow further separation between groups and treatment types and 
could provide information on their effect on neurocognitive function. In particular, whole 
brain radiotherapy particularly at a young age is the treatment which has been more 
closely associated with neurocognitive decline and only one of the patients received 
this treatment. In addition, there was no formal data available relating to neurocognitive 
testing and so we cannot be certain that their cognitive status was low compared with 
healthy volunteers. 
A study by Blamek et al (111) looked at the metabolite profiles of a group of 24 patients 
aged 4-18 years who had received combined treatment for brain tumours. Spectra 
were acquired at three different time points after therapy: between 3 and 6 months, 8-
12 months and approximately 18 months after treatment. Mean NAA/Cr values of 0.91, 
0.91 and 0.86 were found respectively suggesting a decrease in neurological function 
over time. In comparison, our study found a slightly higher range of tNAA/tCr values of 
between 1.31-1.86. For our study, spectra were acquired for a region that had no 
previous history of disease. Whereas, the study by Blamek et al acquired spectra for 
both the tumour bed and contralateral to the tumour bed. The closer proximity to the 
original tumour site could explain the differences found between our studies. 
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A limitation of this study is that our comparator cohort of “normals” is small and are not 
age matched. We have not compared to literature “normals” as the area from which 
spectra are acquired can vary between studies. Metabolite concentrations can vary 
throughout the brain, therefore a more direct comparison with almost identical grid 
positioning was preferred. Another limitation is that these “normals” were sampled from 
university research students which may have higher than average tNAA. A previous 
study by James Davison et al (116) looked at use of single voxel spectroscopy to look 
at brain parieto-occipital white matter metabolite concentrations in subjects with Hunter 
Syndrome. These patients had various degrees of neurocognitive disability. A 
comparison was made with a cohort of children with normal appearing MRI but who 
had undergone MRS due to suspected neurodegenerative and neurocognitive 
conditions. White matter tNAA concentrations were found to be significantly reduced 
P<0.01 for the patients with Hunters Syndrome and to a lesser extent for Basal Ganglia 
grey matter (P<0.05). This validates the use of spectroscopy in the detection of 
neurocognitive dysfunction. The use of MRSI to image white matter as per our protocol 
would allow more information about regions of neurological deficit within the brain to 
be obtained for patients with suspected neurodegeneration. 
A study by Lugar et al (115) found that by using MR Imaging that the Wolfram patients 
had lower fractional anisotropy and higher radial diffusivity in major white matter tracts 
and lower volume regions within the brain e.g. cerebellar white matter. These findings 
reflected the subjects’ neurological symptoms. As far as the authors are aware this is 
the first study to look at the use of MR spectroscopy for subjects with Wolfram 
Syndrome. Within this study, tNAA concentrations, ratios tNAA/tCho and tCho/tCr were 
found to be significantly different from “normals”. This would merit further investigation 
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with a larger cohort into the use of 2D Fast-MRSI protocols to identify metabolite 
biomarkers for the detection of neurodegeneration in Wolfram Syndrome patients. 
5.5 Conclusion 
A fast 2D-MRSI protocol with absolute metabolite quantitation has been implemented 
successfully for two patient groups: Wolfram and Brain Tumour Survivors. Spectra 
had acceptable data quality with respect to SNR and Water Line Width. Minimal 
voxel loss was found for the majority of patients within this study. The protocol was 
also able to distinguish between the Wolfram cohort and healthy volunteers 
demonstrating its feasibility for use in the clinical environment.  
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6. 3D MRSI: A Feasibility Study 
6.1 Introduction 
The ability to acquire accurate whole brain metabolite information has attracted great 
interest within both the research and clinical environment. Acquiring spectra across 
multiple slices would provide greater insight into metabolism throughout the brain. It 
would have great value for pathologies where the location of diseased tissue is not 
previously known, for example tumours; where the heterogeneity may not necessarily 
lie in the axial plane. Long acquisition times and poor-quality data e.g. due to lipid 
contamination from the scalp have hindered the introduction of 3D MRSI into clinic. 
The use of fast-MRSI techniques such as: parallel imaging e.g. sensitivity encoding 
(SENSE) , Reduced Resolution (12), Compressed Sensing (103) or methods which 
reduce the order of phase encoding by one dimension, e.g. Echo Planar Spectroscopic 
Imaging (EPSI) (16,17), have all been proposed to address the long acquisition times 
associated with 3D MRSI acquisition. As seen in chapter four, sensitivity encoding 
proved to be a more accurate technique in reproducing the fully sampled data when 
compared to the reduced resolution technique.  As EPSI and compressed sensing are 
not yet readily available on clinical scanners, this chapter focuses on the use of 
sensitivity encoding for fast-MRSI 3D acquisition with absolute quantification.  
Effective lipid suppression is needed to prevent lipid signal bleed through from the 
scalp due to its high lipid content. A number of methods have been proposed to prevent 
lipid contamination. One approach is to avoid the excitation of the lipid signal itself by 
using a localisation sequence such as PRESS excitation. However, a disadvantage of 
this method is restriction in voxel placement. PRESS and its associated rectangular 
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VOI means it does not conform completely to the round shape of the head. An 
additional/ alternative method is to use outer volume suppression pulses to suppress 
the lipid signal by conforming to the lipid regions (117). Unfortunately, this can add 
complexity to the 3D MRSI planning stage meaning it takes longer to plan and is less 
reproducible. Another method is to apply an inversion pulse, with specific inversion 
time TI, to null the lipid signal and leaving the metabolite signal inverted. This takes 
advantage of the differences in T1 for the lipid and metabolite signals, allowing only 
the metabolite signal to be extracted. The latter was chosen for this study as it would 
allow a multi-slice brain spin-echo sequence to be acquired, making it easier to plan 
and would result in better sampling across the brain. 
 A number of studies have looked at the development of 3D MRSI protocols 
(71,75,118–122). These vary in methodology from the use of EPSI (75,122) or PRESS 
(71,121) sequences and the use of SENSE (120). Reproducibility studies (71,75,123–
125) also vary in methodology e.g. pulse sequence design, field strength and 
quantitation. As far as the authors are aware this is the first study to look at the 
reproducibility of SENSE for a 3D spin echo acquisition as an alternative to less readily 
available techniques. 
In this study, we aimed to optimise a 3D MRSI protocol that could be used clinically 
with an acquisition time of approximately 10 minutes. We tested the robustness of 
sensitivity encoding for its use in fast 3D MRSI acquisitions by comparing the use of 
SENSE against a fully sampled (No SENSE) acquisition. We achieved this by 
assessing the reproducibility of both these acquisition types across multiple healthy 
volunteers. We also looked at the data quality and the efficacy of the applied lipid 
suppression in order to assess if SENSE resulted in any degradation in data quality.  
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6.2 Methods 
6.2.1 2D MRSI Data Collection and Optimisation 
All MR Scanning was performed on a 3T Philips Achieva TX MR System using a 32-
channel head coil at Birmingham University Imaging Centre (BUIC), UK. For this study, 
full ethical approval and informed consent was obtained for all subjects.  
6.2.1.1 Lipid Suppression Optimisation 
Firstly, protocol optimisation steps were carried out in 2D for echo time, lipid 
suppression and water suppression and then were applied to the 3D acquisition. In 
order to establish an optimal protocol to suppress the lipid signal; healthy volunteer 2D 
Spin Echo MRSI acquisitions were acquired with SPectral Attenuated Inversion 
Recovery (SPAIR) applied. The following parameters were used; an offset of 600Hz, 
PB Volume shim, inversion time TI range: 190, 200, 210, 240, 250 and 260ms. 2D 
MRSI grids were manually placed above the Corpus Callosum with the following 
acquisition parameters: half echo acquisition, TE/TR 35/2000ms, Field of View (FOV) 
matrix size 15x13, voxel size 13x13x13mm and sharp RF pulse set. Water suppressed 
and unsuppressed spectra were acquired for each inversion time. Lipid maps were 
generated across the whole 15x13 grid. Lipid content was calculated using the 
absolute sum between 1.0 and 1.9ppm divided by the mean water amplitude. The 
mean lipid content across this grid was then calculated for each inversion time and the 
data quality assessed for SNR and water line width. From these results (see section 
6.3.1) an inversion time of t=250ms was established as optimum. 
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6.2.1.2 Water Suppression Optimisation 
To ascertain the optimal water suppression technique and echo-time a healthy 
volunteer 2D Spin Echo MRSI scan was acquired for three different water suppression 
parameters at two echo times 18 and 35ms. Spectra were acquired using the following 
water suppression parameters: (i) Excitation pulse with second pulse angle at 300°, (ii) 
Excitation pulse with second pulse angle at 550° and (iii) Multiple Optimisations 
Insensitive Suppression Train (MOIST). To assess the success of the water 
suppression techniques the mean water residual divided by the water amplitude across 
the whole grid was calculated for each of these scan acquisitions. The acquisition with 
the lowest water residual was deemed the best. From these results (see section 6.3.2) 
water suppression technique (ii) Excitation with second pulse angle at 550° proved to 
be the most successful across both echo times. 
6.2.1.3 Echo Time Optimisation 
In order to establish the optimum echo time a volunteer scan was acquired to assess 
the reproducibility and data quality for two short echo times TE=18 and 35ms. 2D Spin 
Echo MRSI scans were acquired in triplicate and the reproducibility was assessed 
using Coefficients of Variance (COV) defined as the standard deviation/mean for the 
following metabolites: tNaa, tCr, tCho, Glx, Ins, Glth and Tau. The voxel wise COV was 
calculated and a mean COV determined across the whole MRSI grid. From these 
results (see section 6.3.3) an echo time of 18ms was chosen for the 3D MRSI 
acquisition development.  
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6.2.3 3D MRSI Data Collection and Optimisation 
The optimised parameters were then applied to the following 3D MRSI acquisition. 
Data was collected from four healthy volunteers (aged between 20 and 30). For MRSI 
grid positioning, an initial T1 weighted 3D Magnetization-Prepared Rapid Acquisition 
Gradient Echo (MPRAGE) reference scan was obtained. The 3D MRSI acquisition was 
set up in multi slice mode with a total three slices. All MRSI grid positioning were 
manually placed so the central slice was above with the corpus callosum (Figure 6-3) 
for a 3D Spin Echo sequence with the following acquisition parameters: Field of View 
(FOV) matrix size 15x13; voxel size 13mm x 13mm x 13mm; TE=18ms; TR=2s; half 
echo acquisition mode; RF Pulse normal; Pencil Beam (PB) Volume Shim; SPAIR with 
inversion time t=250ms with an offset of 600Hz; Excitation water suppression with 
second pulse angle 550°. Water unsuppressed data was also collected for all studies 
for metabolite quantitation. A fully sampled (No SENSE) acquisition was acquired for 
one volunteer with an acquisition time of 18 minutes and 42 seconds. Three volunteer 
scans were acquired with SENSE factor Anterior-Posterior (AP) R=2 and Right-Left 
(RL)=1 with an acquisition time of 11minutes and 8 seconds. To assess the short-term 
reproducibility of these all 3D MRSI acquisitions were acquired in triplicate for each 
volunteer without grid repositioning; reshimming and water suppression frequency 
optimization in between scans was performed if deemed necessary.   
6.2.4 3D MRSI Data Analysis 
All spectral analysis was performed using the TARQUIN software package (24). MRSI 
spectra exported from the scanner workstation in SDAT format were imported into 
TARQUIN. Spectra were fitted using the Ex.BL basis set outlined and developed in 
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Chapter 3. A residual water filter cut off of 120Hz was set within the TARQUIN pre-
processing options in order to remove any residual water signal from the analysis. 
Subsequent data analysis was performed using python programming language. The 
data was split into the individual slices: Top (Slice 3), Middle (Slice 2) and Bottom (Slice 
1). The volume of interest (VOI) was extracted using a water amplitude threshold of 
50%. Data quality parameters Water Line width (FWHM) and Signal to Noise (SNR) 
were compared across slices and volunteers. Lipid maps were generated and the 
mean lipid content calculated for each volunteer and slice to assess the success of the 
SPAIR lipid suppression technique. 
Metabolite coefficients of variance (COV) were calculated as the voxel wise ratio of the 
standard deviation and mean for each volunteer and for each slice over the three MRSI 
acquisitions for the voxels which satisfied the quality control criteria of a water line 
width <0.1ppm (12.8Hz). Once again, the unsuppressed water peak FWHM was taken 
to be our measure of data quality due to its robustness in comparison to metabolite 
line width which can become unstable due to noise and artefacts. We also assume that 
the water line width is directly correlated with metabolite FWHM and therefore can be 
used as a proxy for data quality. COV’s for the metabolites tNAA, tCr, tCho, Ins and 
Glx were calculated to assess the technical reproducibility of the SENSE 3D 
acquisitions compared to the fully sampled (No SENSE) acquisition. The number of 
voxels lost due to the water line width criteria was also evaluated for each volunteer 
and slice to assess the robustness of the 3D acquisition and highlight any issues due 
to voxel placement. 
It is worth noting that this analysis focused on the average across voxels in order to 
ease the ability to make direct comparisons between techniques and subjects. 
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Although an advantage of MRSI is the increase in spatial specificity for individual 
cases, when comparing multiple subjects’ due to the large amount of data acquired an 
average comparison is more suitable. 
6.3 Results 
6.3.1 Lipid Suppression Optimisation 
To determine the optimum inversion delay for most effective lipid suppression a healthy 
volunteer 2D MRSI spectra was acquired using SPAIR for the following inversion delay 
times: 190, 200, 210, 240, 250 and 260ms. Figure 6-1 and Table 6-1 show the mean 
lipid values across the whole MRSI grid.  
 
Figure 6-1 Mean Lipid across the MRSI grid for a Healthy Volunteer Spectra for 
multiple SPAIR Inversion Delay times 
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Table 6-1 Mean Lipid Values for SPAIR Pulse Inversion Delay range 190ms to 
260ms 
Inversion Delay (ms) Mean Lipid (AU) Standard Deviation 
190 14.43 15.98 
200 12.33 12.33 
210 10.11 10.48 
240 5.90 4.41 
250 5.04 4.34 
260 6.85 4.91 
 
An inversion delay of 250ms proved to be superior in the reduction of lipid levels with 
the lowest mean lipid value of 5.04. The data quality was also assessed with the mean 
water FWHM and SNR max calculated across the MRSI grid (Table 6-2).  
Table 6-2 Mean SNR max and Water Line Width Values for each Inversion Delay 
Inversion Delay 
(ms) 
Water FWHM 
(PPM) 
Standard 
deviation 
(PPM) 
SNR max Standard 
deviation 
(PPM) 
190 0.093 0.023 32.80 2.16 
200 0.091 0.021 31.46 1.69 
210 0.092 0.023 30.27 7.04 
240 0.090 0.020 19.44 2.60 
250 0.091 0.020 21.63 3.38 
260 0.092 0.020 17.13 2.24 
 
Low variation in water line width was observed across the above inversion delay times. 
All mean water line width values were found to be below the rejection criteria of 
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0.1ppm.  Acceptable SNR of 21.63 was observed for an inversion delay of 250ms. 
Following on from these results an inversion delay of 250ms proved to optimal in the 
suppression of unwanted lipid signals and was applied in our protocol from this point 
forward. 
6.3.2 Water Suppression Optimisation 
Three techniques were assessed in their effectiveness for suppression of the water 
peak: Excitation pulse with a second pulse angle of 300°, Excitation with a second 
pulse angle of 550° and MOIST. This was done for two echo times; 18 and 35ms. Their 
water suppression efficacy was assessed by calculating the mean water residual, 
taken from the sum of the spectral components between 4 and 5ppm normalised to 
the mean water amplitude (Table 6-3 and Figure 6-2). 
Table 6-3 Whole MRSI Grid Mean Water Residual Values normalized to the 
Water Amplitude for Echo times 18ms and 35ms 
TE 
(ms) 
Water Suppression 
Technique 
Whole Grid Mean Water 
Residual/Water 
Amplitude (AU) Standard Deviation 
35 
Excitation 2nd PA 300° 175 144 
Excitation 2nd PA 550° 169 121 
MOIST 366 214 
18 
Excitation 2nd PA 300° 228 256 
Excitation 2nd PA 550° 210 127 
MOIST 408 169 
From these results, the Water Suppression Technique; Excitation with a Second Pulse 
Angle of 550° had the lowest water residual of 169 and 210 for echo times of 35 and 
18ms respectively. MOIST had the worst performance with water residual of 366 and 
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406 approximately two times higher than by using an Excitation Pulse. Water 
suppression through Excitation with a second pulse angle of 550° was therefore 
deemed optimal and was chosen for the remainder of this study. 
 
 
Figure 6-2 Mean Water Residual Measurement comparing Echo time and Water 
Suppression Techniques 
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6.3.3 Echo Time Optimisation 
 In order to establish an optimum echo time to apply to our 3D MRSI protocol, with 
inversion recovery based lipid suppression, the reproducibility of two echo times 
TE=35ms and TE=80ms was assessed. Healthy volunteer 2D MRSI scans were 
acquired in triplicate and the mean Coefficients of Variance calculated for the following 
metabolites: tNaa, tCr, tCho, Glx, Ins, Glth and Tau (Table 6-4).  
Coefficients of Variance are comparable between echo times across the majority of 
the metabolites. However, improved reproducibility was observed for Ins. Data quality 
parameters Water line width and SNR were also comparable between echo times. 
Therefore, an echo time of 18ms was chosen to be applied to the 3D MRSI acquisitions 
within this chapter due its improved Ins reproducibility and acceptable data quality.   
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Table 6-4 Metabolite Coefficients of Variance for TE=18 and 35ms 
  
Coefficient of variance % 
TE (ms) tNAA tCr tCho Glx Ins Glth Tau 
18 3.35 4.30 6.80 10.87 7.78 28.29 27.19 
35 2.92 4.02 5.92 11.14 13.54 26.48 22.77 
 
Table 6-5 Mean Water Line Width and SNR Values for TE=18 and 35ms 
TE (ms) 
Water FWHM 
(ppm) 
Standard 
Deviation 
SNR 
max 
Standard 
Deviation 
18 0.07 0.01 20.30 3.74 
35 0.07 0.01 22.69 5.25 
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6.3.4 Lipid suppression using Optimised 3D MRSI SPAIR acquisition.  
Three-dimensional MRSI acquisitions (three slices) with SPAIR were acquired for four 
healthy volunteers. The MRSI grids were placed manually with the central slice aligned 
with the corpus callosum (Figure 6-3).  
 
Figure 6-3 3D MRSI Planning Grid Placement for healthy volunteer 2 scan with 
Saggital (A), Coronal (B) and Axial (C) Views. Water Line Width (PPM) maps for 
the three axial slices: Top (D), Central (E) and Bottom (F) slices. 
From this point forward the Top, Middle and Bottom slices will be referred to as Slice 
3, 2 and 1 respectively. “No SENSE” volunteer acquisition was acquired with no 
SENSE factor applied. Volunteers 1, 2 and 3 were acquired with a SENSE factor of 2 
in the anterior-posterior (AP) direction and 1 in the Right-Left direction (RL). 
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The mean lipid values for each slice were calculated for each volunteer (Table 6-6) 
across the whole MRSI grid.  
Table 6-6 Mean Lipid Values (AU) across all slices for No SENSE and SENSE 
factor AP 2 and RL 1 (Volunteer 1-3) 
  Slice 1 Slice 2 Slice 3 
  
Mean Lipid/ 
mean 
Water 
Amplitude 
(AU) 
Standard 
Deviation 
Mean Lipid/ 
mean Water 
Amplitude 
(AU) 
Standard 
Deviation 
Mean Lipid/ 
mean 
Water 
Amplitude 
(AU) 
Standard 
Deviation 
No SENSE 6.71 5.42 6.69 5.37 7.34 6.47 
Volunteer 1 7.21 5.03 9.32 6.43 8.70 7.67 
Volunteer 2 8.38 5.36 9.54 6.93 9.44 8.56 
Volunteer 3 6.41 4.72 7.45 5.59 7.99 6.80 
 
Mean lipid values were lowest across all volunteers for Slice 1 (bottom) with higher 
lipid content observed for Slice 2 and 3 this can also be observed in Figure 6-4 which 
shows the distribution of the lipid across the whole MRSI grid. As expected the majority 
of lipid signal is located around the edge of the brain consistent with the CSF between 
the brain and skull. Large standard deviation is therefore observed across the grid 
(Table 6-6). Fully optimal lipid suppression is not fully effective for this region due to 
the high lipid signal contribution, however by comparison the majority of the in-brain 
volume lipid signal is much lower (approximately x4 in most regions). As this is the 
region we are interested in for quantification this validates the effectiveness of our 
optimised lipid suppression technique. 
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Figure 6-4 Volunteer Lipid Maps with (Volunteer 1,2 and 3) and without SENSE 
(No SENSE) for each image slice: Slice 3 (A, D, G and J), Slice 2 (B, E, H and K) 
and Slice 1 (C, F, I and L). 
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6.3.5 The Effect of SENSE on 3D MRSI Reproducibility 
Scans were acquired in triplicate in order to test the robustness of our 3D acquisition. 
Reproducibility was assessed using Coefficient’s of Variance (CoV) (Table 6-7 and 6-
8). Water suppressed and water unsuppressed scans were acquired for metabolite 
quantitation.  
Overall, across all slices the mean coefficients of variance are comparable between 
SENSE and no SENSE for all metabolites. However, variation can be observed across 
the three slices. For tNAA the middle slice (Slice 2) offers the most comparable 
coefficient of variance when comparing the no SENSE and SENSE volunteer 
acquisitions. For slice 1 and 3 the tNAA CoV’s showed increased or even decreased 
variation across the volunteers with and without variation. Suggesting the addition of 
variation due to differing brain anatomy between volunteers may be a factor. This 
fluctuation of variation across slices and volunteers can also be observed for all other 
metabolites.  
The most reproducible metabolite using this method was found to be tNAA with 
coefficients of variance of 10.04 with no SENSE and 12.73, 12.68 and 9.60% for 
volunteer 1, 2 and 3 respectively (Table 6-7). Increased variation across all volunteers 
was observed for tCr and tCho with a mean CoV’s <25% for all slices combined. Slice 
1 (lowest slice) for volunteer 2 was consistently higher for these metabolites, further 
suggesting inter-subject anatomical variability may influence the obtainable 
reproducibility from this technique. 
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Table 6-7 Mean metabolite Coefficients of Variance % for tNAA, tCr and tCho for No SENSE and SENSE Factor AP 
R=2 and RL = 1 (Volunteer 1-3). 
  tNAA CoV % tCr CoV % tCho CoV % 
  
Slice 
1 
Slice 
2 
Slice 
3 All 
Slice 
1 
Slice 
2 
Slice 
3 All 
Slice 
1 
Slice 
2 
Slice 
3 All 
No SENSE  8.37 7.32 14.44 10.04 19.22 9.09 22.73 17.01 14.45 9.64 15.13 13.07 
Volunteer 
1 17.01 9.84 11.34 12.73 21.74 10.59 18.76 17.03 25.31 14.48 23.12 20.97 
Volunteer 
2 21.62 11.03 5.40 12.68 28.49 16.67 9.71 18.29 35.13 19.79 19.20 24.71 
Volunteer 
3 8.43 12.01 8.37 9.60 14.51 11.57 11.45 12.51 24.25 21.23 16.15 20.54 
Volunteer 
1-3 15.69 10.96 8.37 11.67 21.58 12.94 13.31 15.94 28.23 18.50 19.49 22.07 
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Table 6-8 Mean metabolite Coefficients of Variance % for Glx and Ins for No SENSE and SENSE Factor AP R=2 and 
RL = 1 (Volunteer 1-3). 
  Glx CoV % Ins CoV% 
  
Slice 
1 
Slice 
2 
Slice 
3 All 
Slice 
1 
Slice 
2 Slice 3 All 
No SENSE  32.92 22.21 23.34 26.15 20.00 30.25 22.07 24.11 
Volunteer 
1 34.03 39.93 23.22 32.39 42.46 30.39 23.84 32.23 
Volunteer 
2 50.98 50.98 27.00 42.98 37.06 24.24 20.70 27.33 
Volunteer 
3 25.62 22.68 30.42 26.24 30.41 27.62 27.05 28.36 
Volunteer 
1-3 36.88 37.86 26.88 33.87 36.64 27.42 23.86 29.31 
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From Table 6-8 it can be seen that as expected the highest variation can be found for 
the lower level metabolites Glx and Ins. An increase in variation <20% is observed for 
all slices with the addition of a SENSE factor of AP 2 RL 1.  
Overall, increased variation is observed for slice 1 and 3 across all volunteers. Due to 
the close proximity of slice 1 to the sinuses (air-tissue interface) and slice 3 to the top 
of the skull where there may be a higher chance of lipid contamination and reduced 
shimming efficacy.  
6.3.6 The Effect of Water Line Width and Data Quality on 3D MRSI 
Reproducibility 
As the CoV’s were calculated from the voxels that met a water line width criteria of 
below 0.1ppm. The number of voxels discarded due to this was also calculated (Figure 
6-5 and Table 6-9) as a smaller sample voxel size could affect the overall statistics. 
The SNR for No SENSE and SENSE factor R: AP R=2 and RL = 1 was also 
investigated across the different slices. 
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Figure 6-5 Percentage voxel loss due to Water Line Width Criteria <0.1ppm 
across all volunteers and slices for No SENSE and with SENSE Factor R: AP 2 
and RL=1 
 
It can be seen from Figure 6-5 that the highest percentage of voxels lost was found for 
slice 1 and 3 across all volunteers. No SENSE had the best performance overall with 
34% of voxels lost across all slices (Table 6-9). The use of SENSE for Volunteer 1 and 
Volunteer 2 showed an increased % loss of approximately 10% with Volunteer 3 
performing the worst with 70% of the voxels lost within the brain volume. The poorer 
performance for volunteer 3 could be accounted for due to anatomical differences or 
movement. The main contribution of voxels lost attributed to slice 1 and slice 3 
suggests the effect of shimming in these more difficult to image areas has had a large 
impact on data loss due to the water line width criteria.  
Figure 6-6 shows example tNAA coefficients of variance maps for Volunteer 2 before 
and after the line width criteria was applied in order to localise the regions of voxel 
loss. The majority of voxels for slice 1 and 2 were lost in the frontal region of the brain. 
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This is consistent with locality to the sinus air-tissue interface where it is known 
shimming can be an issue. This, consistent with data collected in chapter 3, we believe 
is the cause of voxel loss here for these slices. Slice 3 shows the greatest % voxel loss 
with only 8 voxels remaining for this slice after the Water Line Width criteria is applied. 
We believe this is due to the close proximity of this slice to the skull. As once again the 
scanner struggles to shim across bone this could have introduced further peak 
broadening. Thus, these voxels will be removed due to our rejection criteria.  
 
Figure 6-6 Example tNAA Coefficients of Variance maps showing voxel loss for 
Volunteer 2 for: Slice 3 (A and D), Slice 2 (B and E) and Slice 1 (C and F) for 
Before and After the Water Line Width criteria <0.1ppm was applied 
respectively. 
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Table 6-9 Number of voxels within the brain volume Before and After a Water Line Width Criteria of <0.1ppm for all 
slices and volunteers. A percentage of voxels lost due to this rejection criteria is also shown. 
Slice 1 Slice 2 Slice 3 All 
  Before After % Voxels lost Before After 
% 
Voxels 
lost 
Before After 
% 
Voxels 
lost 
Before 
QC After 
% 
Voxels 
lost 
No 
SENSE 70 40 43 56 47 16 46 27 41 172 114 34 
Volunteer 
1 79 44 44 60 42 30 52 18 65 191 104 46 
Volunteer 
2 76 51 33 65 47 28 49 8 84 190 106 44 
Volunteer 
3 70 16 77 65 32 51 44 6 86 179 54 70 
Volunteer 
1-3 75 37 51 63 40 36 48 11 78 187 88 53 
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Table 6-10 Mean SNR max and Water Line Width and corresponding Standard Deviation values calculated across all 
volunteers and slices for voxels with a line width criteria of <0.1ppm. 
 
 
Mean SNR max Mean Water FWHM (PPM) 
 Slice 
1  
Slice 
2  
Slice 
3  All  
Slice 
1  Slice 2  
Slice 
3  All  
No SENSE 12.91 4.64 19.49 4.62 18.48 6.75 16.96 4.70 0.08 0.01 0.07 0.01 0.08 0.01 0.08 0.01 
Volunteer 
1 13.83 4.49 15.06 3.50 18.55 2.34 15.81 3.08 0.08 0.01 0.07 0.01 0.08 0.01 0.08 0.01 
Volunteer 
2 11.59 4.60 16.00 3.45 20.29 2.33 15.96 3.10 0.07 0.01 0.08 0.01 0.08 0.00 0.08 0.01 
Volunteer 
3 7.71 1.76 12.24 3.00 14.52 3.49 11.49 2.46 0.06 0.02 0.08 0.01 0.09 0.00 0.08 0.01 
Volunteer 
1-3 11.04 3.33 14.43 2.88 17.79 2.40 14.42 2.51 0.07 0.01 0.08 0.01 0.08 0.01 0.08 0.01 
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Table 6-10 shows the mean SNR and water line width values for each volunteer and 
slice. It can be seen that overall across all slices the use of SENSE creates a small 
reduction in SNR. Mean SNR values for voxels with a water line width <0.1ppm are 
still within acceptable limits (>5). Slice 1 (lowest slice) had the lowest SNR across all 
volunteers. The mean water line width across voxels meeting this criterion are 
unchanged through the addition of SENSE. Figure 6-7 shows SNR maps across the 
whole grid for all voxels within the brain volume. SNR varies across the slices for each 
volunteer and within the regions themselves. Voxels with high signal can be observed 
on the edges which could be attributed to lipid bleed through due to their close 
proximity to voxels with high lipid signal (Figure 6-4). Figure 6-3 D, E and F shows the 
Water FWHM map for volunteer without the rejection criteria. Increased line width can 
be observed in the frontal regions of the brain across all slices. This is consistent with 
previous results in chapter 3.  
Overall, the data quality was acceptable across all slices with mean SNR values 
greater than 5 across all slices and with the addition of a SENSE factor R AP=2 and 
RL=1. The number of voxels lost due to the water line width criteria; 34% with no 
SENSE, 46, 44 and 70% for volunteers 1, 2 and 3 respectively is high. The mean 
percentage of voxels lost is 53% with SENSE across these volunteers. The addition of 
SENSE resulted in ~20% increase in voxel loss.   However, a large number of voxels 
remained particularly for slices 2 and 3. This suggests the use of a 3D acquisition 
would provide more data than a single slice 2D acquisition as more metabolite 
information could be mapped across the brain instead of one region.  
 128 | P a g e  
 
 
 
Figure 6-7 In volume SNR max maps for each volunteer for Slice 3 (A, D, G and 
J), Slice 2 (B, E, H and K) and Slice 1 (C, F, I and L) with no water line width 
threshold applied. 
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6.4 Discussion 
The purpose of this study was to validate the use of SENSE for the collection of 3D 
MRSI data with absolute quantification of metabolites. A number of optimisation steps 
were carried out in order to design a protocol with effective lipid and water suppression. 
The reproducibility of healthy volunteer acquisitions with sensitivity encoding AP R=2 
RL R=1 were compared to a fully sampled (No SENSE) healthy volunteer acquisition. 
Reproducibility was assessed using Coefficients of Variance (CoV’s). Mean SNR and 
Water line width values were also compared and mean lipid values calculated to 
assess the effectiveness of lipid suppression using SPAIR. Voxel loss due to a water 
line width criterion was also determined for each acquisition.  
Overall, data quality was found to be acceptable with the use of SENSE. Similarly, a 
study by Ozturk-Isik et al (120)  found the use of sensitivity encoding in 3D MRSI 
produced acceptable SNR for Cho, Cr and NAA and also found the data was clinically 
interpretable. Mean coefficients of variance for all slices combined was comparable 
between No SENSE and SENSE. However, increased variation was observed 
between slices, with the middle slice 2 being the most robust. The most reproducible 
metabolite was found to be tNAA with higher CoV’s found for tCr and tCho. Further 
variability was found for Glx and Ins. Mean volunteer coefficients of variance of 11.67% 
for tNAA, 15.94% tCr, 22.07% for tCho, 33.87% Glx and 29.31% for Ins were found for 
volunteers with the addition of SENSE Factor AP R=2 and RL = 1.  
Ding et al (75) found comparable intra subject coefficients of variance of 14%, 15%, 
20%, 31% and 31% for tNAA, tCr, tCho, Glx and Ins respectively. This study used EPSI 
combined with parallel imaging (acceleration factor 1.6) to collect 18 slices for a 50 x 
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50 FOV in an acquisition time of 16 minutes. A comparable line width threshold of 11Hz 
was also used as a rejection criterion for voxels containing poor quality spectra.  
However, the number of voxels discarded due to this criterion is not stated. Our study 
acquired 3 slices in 11 minutes 8 seconds which although fewer slices were acquired 
throughout the brain this acquisition would fit within a clinical scanning session more 
easily. This acquisition time could be reduced further if a higher SENSE factor was 
applied to the water unsuppressed acquisition as discussed in chapter 4. The addition 
of compressed sensing (126) although not readily available could also provide a further 
reduction in scan time and would make an interesting extension to this study. Further 
slices could therefore be acquired in order to obtain a whole brain MRSI acquisition.  
Li et al (123) also assessed the intra-subject reproducibility of a 3D MRSI protocol 
using PRESS finding comparable COVs of 13.8%, 18.5% and 20.1% for tNAA, tCr and 
tCho respectively for a long TE = 135ms. This acquisition however took 54 minutes 
which would not be feasible in a clinical setting.  Langer et al (71) also used PRESS 
and found comparable coefficients of variance of 13.5%, 21.7%, 18.3%, 24% and 21% 
for tNAA, tCr, tCho, Glx and Ins respectively for an echo time of 30ms. Our study found 
slightly higher COV’s for tCho, Glx and Ins.  Langer et al used a Gill-Thomas- Cosman 
(GTC) stereotactic head frame which may have reduced variability due to patient 
motion. The limitation of the excitation to the PRESS box would also reduce variation 
due to lipid contamination. Four 5x5 voxel slices (100 voxels) were acquired with an 
acquisition time 12minutes 54 seconds. By comparison our study provided a similar 
number of acceptable quality voxels even after the line width criterion was applied.  
The introduction of sensitivity encoding resulted in increased percentage voxel loss; 
<15% for Volunteer 1 and 2 and 36% increase for Volunteer 3. However, a comparable 
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number of voxels remained ~100 for No SENSE, Volunteer 1 and Volunteer 2. The 
largest number of voxels were lost for Volunteer 3.  Suggesting inter-subject variability 
could be a factor in the implementation of this 3D MRSI protocol. Ding et al (75) found 
inter-subject COV’s were up to 6% higher than those for intra-subject variability. 
Further investigation involving more subjects with our proposed 3D MRSI protocol 
would be needed to assess this further.  
Lipid interference appears to be higher in the SENSE acquisitions compared to the 
acquisition with No SENSE factor applied. Kirchner et al (127) found that the SENSE 
reconstruction algorithm can cause the voxels to be susceptible to the effects of lipid 
signal bleed through, which could explain the higher lipid content observed within this 
study. As the SPAIR lipid suppression pulse does not have the ability to fully suppress 
the lipid signal, this method maybe limited in its effectiveness particularly in regions 
close to the scalp. The use of saturation bands placed over the scalp, although adding 
extra complexity to the MRSI planning stages, may offer assistance in the suppression 
of these outer volume lipid signals. 
6.5 Conclusion 
Overall, we have developed a 3D MRSI spin echo protocol that would allow metabolite 
information to be mapped through the brain for three slices as an alternative to less 
readily available techniques. Metabolite CoV’s were calculated in order to test the 
robustness of this protocol with good results. We were able to obtain metabolite 
information with good SNR and water line width across more regions than would be 
attainable with a 2D acquisition. This protocol has been optimised to minimise the 
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effects of lipid contamination and inefficient water suppression which would allow more 
robust metabolite information to be mapped throughout the brain. 
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7. Conclusions and Further work 
7.1 Objective 1- Investigation into the effect of both acquisition parameters 
and fitting methods on 1H MRSI Reproducibility 
The first objective was to look at the effect of both acquisition parameters i.e. short or 
long echo time and fitting methods i.e. fitting models on the reproducibility of 1H MRSI 
data. This was achieved through the assessment of both echo time (TE=35, 80 and 
144ms) and two macromolecular (MM) baseline analysis schemes simulated (Si.BL) 
and experimentally derived (Ex.BL) and their influence on reproducibility. Both the 
choice of MM analysis scheme and echo time were found to have an impact on the 
reproducibility of 1H MRSI data. These results highlighted the importance of careful 
echo time selection and analysis methodology. For optimal reproducibility, the primary 
metabolite of interest should be taken into consideration. Overall, this study found that 
an intermediate echo time of 80ms produced the most reproducible metabolite values 
for tNAA, tCho, tCr and Glth in healthy volunteers. However, the combined use of a 
short TE sequence and the MM analysis scheme Ex.BL could be recommended as a 
result of this study as a compromise between good accuracy, good SNR and T2 bias 
on metabolite estimates.  
7.1.1 Future Work 
It has been established in a number of studies (52,56,63,92,93) that the MM content 
within the brain varies between different pathologies. Therefore, an interesting 
extension to this project would be to investigate the development of disease specific 
experimental macromolecular analysis schemes to assess if any improvement in fitting 
accuracy could be made compared to a healthy volunteer model.  
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The introduction of fast-MRSI methods e.g. SENSE and their effect on the 
reproducibility of 2D MRSI protocols using Ex.BL could also be evaluated. Due to their 
associated SNR losses, investigation into their effect on longer echo time acquisitions 
could also help establish optimal protocols for clinical MRSI studies. Particularly, where 
a reduction in scan time is important. 
Finally, future work could also include the assessment of techniques with respect to 
both reproducibility and accuracy by comparing to normative values. This would 
involve the use of segmentation for white matter, grey matter and cerebral spinal fluid 
(CSF) in order to perform partial volume corrections.   
7.2 Objective 2- Investigation into the effect of fast-MRSI techniques on 
accuracy for water reference data acquisition. 
The second objective was to assess the ability of fast-MRSI techniques to accurately 
reproduce fully sampled water reference data. The use of SENSE for the collection of 
fast-MRSI water reference data within the brain for absolute quantification of 
metabolites was validated through a comparison with a “gold standard” reduced 
resolution technique. Accuracy was assessed by ability to (i) reconstruct fully sampled 
volunteer and phantom data; (ii) reproduce known metabolite concentrations from 
phantom data, and (iii) produce metabolite concentrations from healthy volunteers. 
SENSE proved to be approximately three times more effective and offered significant 
improvement in accuracy over the reduced resolution method.   These findings 
validated the use of SENSE MRSI for the accurate measurement of absolute 
metabolite concentrations in a feasible time frame (~6minutes) for use within a clinical 
setting. 
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7.2.1 Future Work 
The use of compressed sensing, although currently not widely available, in conjunction 
with SENSE would allow a further reduction in scan time. A further study investigating 
the combination of these two techniques and their ability to reconstruct fully sampled 
data, if successful, would further ease the introduction of MRSI into the clinical setting. 
Another extension to this project would be the assessment of increasing SENSE 
factors on the accuracy of metabolite data collection. 
7.3 Objective 3- The use of fast-MRSI techniques in clinical practice. 
The third objective was to implement fast-MRSI techniques into clinical practice. 
Spectra were acquired successfully for two patient groups using the protocol 
developed in Chapter 4. The use of SENSE for fast-MRSI water reference data for 
absolute quantitation of metabolite information in clinic was assessed. Data quality and 
the protocols ability to separate between patient groups Brain Tumor Survivors (BTS), 
Wolfram Patients and “healthy volunteers”. Spectra had acceptable data quality with 
respect to SNR and Water Line Width. Minimal voxel loss was found for the majority of 
patients within this study. The protocol was also able to distinguish between the 
Wolfram cohort and healthy volunteers validating its use in the clinical environment. 
7.3.1 Future Work 
A limitation of this study is the small comparator “normal” cohort, although significant 
differences between “normal” and the Wolfram patient group was observed even with 
this sample size. If further data could be acquired across all groups the use of this 
protocol clinically could be validated further. This would provide more information into 
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the investigation of neuronal dysfunction within different pathologies. The use of an 
age matched “normal” comparator would also help assess the effectiveness of our 
protocol.  
7.4 Objective 4- Development and optimisation of 3D-MRSI protocol  
The final and fourth objective of this study was to develop and optimise a 3D-MRSI 
protocol. A 3D MRSI spin echo protocol was developed that successfully mapped 
robust metabolite information through the brain for three slices. Spectra were acquired 
throughout the brain in a clinically feasible acquisition time of 11 minutes and 8 
seconds using the lipid inversion technique SPAIR. Metabolite CoV’s were calculated 
in order to test the robustness of this protocol with good results. Good SNR and water 
line width across more regions compared to a 2D MRSI acquisition was obtained. This 
protocol had also been optimised to minimise the effects of lipid contamination and 
inefficient water suppression which allows robust metabolite information to be mapped 
throughout the brain. 
7.4.1 Future Work 
Investigation into inter-subject variability would further test the robustness of this 3D-
MRSI protocol. Moderate inter-subject variability was observed within our study for this 
technique. Further Data collection would provide useful information into the success of 
our protocol for a wider subject group. 
The use of a higher SENSE factors on the water reference data would provide a further 
reduction in scan time. Therefore, investigation into different SENSE factors or the 
combined use of compressed sensing once again would further compliment this study. 
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